

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent advances in understanding and managing... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/6-2123/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/6-2123" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent advances in understanding and managing T-cell lymphoma" />
    
            <meta name="og:title" content="F1000Research Article: Recent advances in understanding and managing T-cell lymphoma.">
            <meta name="og:description" content="Read the latest article version by Jun Ho Yi, Seok Jin Kim, Won Seog Kim, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="13616">
            <meta name="article-id" content="12573">
            <meta name="dc.title" content="Recent advances in understanding and managing T-cell lymphoma">
            <meta name="dc.description" content="Owing to the rarity of peripheral T-cell lymphoma (PTCL) and the heterogeneity of subtypes, there are no compelling data to guide the therapeutic approaches for such patients. Over the years, there have been remarkable advances in molecular subtyping and treatment of PTCL, although there are still many areas to be explored. In this review, we summarize recent updates on the evolution of understanding and treatment for PTCL.">
            <meta name="dc.subject" content="T-Cell lymphoma, PTCL, T-lymphocytes, Natural Killer Cells">
            <meta name="dc.creator" content="Yi, Jun Ho">
            <meta name="dc.creator" content="Kim, Seok Jin">
            <meta name="dc.creator" content="Kim, Won Seog">
            <meta name="dc.date" content="2017/12/12">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.12573.1">
            <meta name="dc.source" content="F1000Research 2017 6:2123">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="T-Cell lymphoma">
            <meta name="prism.keyword" content="PTCL">
            <meta name="prism.keyword" content="T-lymphocytes">
            <meta name="prism.keyword" content="Natural Killer Cells">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2017/12/12">
            <meta name="prism.volume" content="6">
            <meta name="prism.number" content="2123">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.12573.1">
            <meta name="prism.url" content="https://f1000research.com/articles/6-2123">
            <meta name="citation_title" content="Recent advances in understanding and managing T-cell lymphoma">
            <meta name="citation_abstract" content="Owing to the rarity of peripheral T-cell lymphoma (PTCL) and the heterogeneity of subtypes, there are no compelling data to guide the therapeutic approaches for such patients. Over the years, there have been remarkable advances in molecular subtyping and treatment of PTCL, although there are still many areas to be explored. In this review, we summarize recent updates on the evolution of understanding and treatment for PTCL.">
            <meta name="citation_description" content="Owing to the rarity of peripheral T-cell lymphoma (PTCL) and the heterogeneity of subtypes, there are no compelling data to guide the therapeutic approaches for such patients. Over the years, there have been remarkable advances in molecular subtyping and treatment of PTCL, although there are still many areas to be explored. In this review, we summarize recent updates on the evolution of understanding and treatment for PTCL.">
            <meta name="citation_keywords" content="T-Cell lymphoma, PTCL, T-lymphocytes, Natural Killer Cells">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Jun Ho Yi">
            <meta name="citation_author_institution" content="Division of Hematology-Oncology, Department of Medicine, Chung-Ang University , Seoul, South Korea">
            <meta name="citation_author" content="Seok Jin Kim">
            <meta name="citation_author_institution" content="Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul, South Korea">
            <meta name="citation_author" content="Won Seog Kim">
            <meta name="citation_author_institution" content="Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul, South Korea">
            <meta name="citation_publication_date" content="2017/12/12">
            <meta name="citation_volume" content="6">
            <meta name="citation_publication_number" content="2123">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.12573.1">
            <meta name="citation_firstpage" content="2123">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/6-2123/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/6-2123.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=13616 /> <input type=hidden id=articleId name=articleId value=12573 /> <input type=hidden id=xmlUrl value="/articles/6-2123/v1/xml"/> <input type=hidden id=xmlFileName value="-6-2123-v1.xml"> <input type=hidden id=article_uuid value=191d0b13-885c-44e1-a3a2-6196ff0434fa /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent advances in understanding and managing T-cell lymphoma"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.12573.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.12573.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/6-2123"
  },
  "headline": "Recent advances in understanding and managing T-cell lymphoma",
  "datePublished": "2017-12-12T11:49:23",
  "dateModified": "2017-12-12T11:49:23",
  "author": [
    {
      "@type": "Person",
      "name": "Jun Ho Yi"
    },    {
      "@type": "Person",
      "name": "Seok Jin Kim"
    },    {
      "@type": "Person",
      "name": "Won Seog Kim"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Owing to the rarity of peripheral T-cell lymphoma (PTCL) and the heterogeneity of subtypes, there are no compelling data to guide the therapeutic approaches for such patients. Over the years, there have been remarkable advances in molecular subtyping and treatment of PTCL, although there are still many areas to be explored. In this review, we summarize recent updates on the evolution of understanding and treatment for PTCL."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/6-2123.html",
            "name": "Recent advances in understanding and managing T-cell lymphoma"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent advances in understanding and managing T-cell lymphoma </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=13616 data-id=12573 data-downloads="" data-views="" data-scholar="10.12688/f1000research.12573.1" data-recommended="" data-doi="10.12688/f1000research.12573.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/6-2123/v1/pdf?article_uuid=191d0b13-885c-44e1-a3a2-6196ff0434fa" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-12573-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-12573-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-12573-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Yi JH, Kim SJ and Kim WS. Recent advances in understanding and managing T-cell lymphoma [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):2123 (<a class=new-orange href="https://doi.org/10.12688/f1000research.12573.1" target=_blank>https://doi.org/10.12688/f1000research.12573.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-12573-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=12573 id=track-article-signin-12573 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/12573?target=/articles/6-2123.html">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=13616 /> <input name=articleId type=hidden value=12573 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent advances in understanding and managing T-cell lymphoma</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Jun Ho Yi<a href="https://orcid.org/0000-0003-1499-7131" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-1499-7131</div><sup>1</sup>,&nbsp;</span><span class="">Seok Jin Kim<sup>2</sup>,&nbsp;</span><span class=""><a href="mailto:wskimsmc@skku.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Won Seog Kim</span></a><sup>2</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Jun Ho Yi<a href="http://orcid.org/0000-0003-1499-7131" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-1499-7131</div><sup>1</sup>,&nbsp;</span><span class="">Seok Jin Kim<sup>2</sup>,&nbsp;</span><span class=""><a href="mailto:wskimsmc@skku.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Won Seog Kim</span></a><sup>2</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 12 Dec 2017 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.12573.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Division of Hematology-Oncology, Department of Medicine, Chung-Ang University , Seoul, South Korea<br/> <sup>2</sup> Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul, South Korea<br/> <p> <div class=margin-bottom> Jun Ho Yi <br/> <span>Roles: </span> Supervision, Writing – Original Draft Preparation </div> <div class=margin-bottom> Seok Jin Kim <br/> <span>Roles: </span> Project Administration, Supervision </div> <div class=margin-bottom> Won Seog Kim <br/> <span>Roles: </span> Supervision, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=28648-28593></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=28646-28596></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Owing to the rarity of peripheral T-cell lymphoma (PTCL) and the heterogeneity of subtypes, there are no compelling data to guide the therapeutic approaches for such patients. Over the years, there have been remarkable advances in molecular subtyping and treatment of PTCL, although there are still many areas to be explored. In this review, we summarize recent updates on the evolution of understanding and treatment for PTCL. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> T-Cell lymphoma, PTCL, T-lymphocytes, Natural Killer Cells </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Won Seog Kim (<a href="mailto:wskimsmc@skku.edu">wskimsmc@skku.edu</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Won Seog Kim </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2017 Yi JH <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Yi JH, Kim SJ and Kim WS. Recent advances in understanding and managing T-cell lymphoma [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):2123 (<a href="https://doi.org/10.12688/f1000research.12573.1" target=_blank>https://doi.org/10.12688/f1000research.12573.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 12 Dec 2017, <b>6</b>(F1000 Faculty Rev):2123 (<a href="https://doi.org/10.12688/f1000research.12573.1" target=_blank>https://doi.org/10.12688/f1000research.12573.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 12 Dec 2017, <b>6</b>(F1000 Faculty Rev):2123 (<a href="https://doi.org/10.12688/f1000research.12573.1" target=_blank>https://doi.org/10.12688/f1000research.12573.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d4678e174>Introduction</h2><p class="" id=d4678e177>T/natural killer (T/NK) cell lymphoma represents a heterogeneous group of malignant lymphoproliferative diseases that arise from T-lymphocytes and NK cells. To distinguish it from immature T-cell neoplasms such as lymphoblastic leukemia/lymphoma, mature T-cell lymphoma is often called peripheral T-cell lymphoma (PTCL). PTCL accounts for approximately 15% of all non-Hodgkin’s lymphoma cases worldwide and shows regional differences in distribution.</p><p class="" id=d4678e180>Over the years, the molecular understanding of PTCL has advanced remarkably; as a result, the classification of PTCL was recently revised<sup><a href="#ref-1">1</a></sup>. In addition, with new combinations of older drugs, novel agents such as checkpoint inhibitors, epigenetic modulators, and anti-folates have been introduced for the treatment of PTCL. Despite this progress, the prognosis for PTCL is worse than that for B-cell lymphoma, even than that before the era of rituximab<sup><a href="#ref-2">2</a>,<a href="#ref-3">3</a></sup>.</p><p class="" id=d4678e194>In this concise review, we provide an overview of the latest advances in the management of PTCL focusing on trials that have been carried out with novel agents. Of note, this review does not cover cutaneous T-cell lymphoma (CTCL) or extranodal NK-T cell lymphoma (ENKTL), because their biological features and treatment strategies differ from those of PTCL.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d4678e200>Brief review of the 2016 World Health Organization revision of nodal/extranodal peripheral T-cell lymphomas</h2><p class="" id=d4678e203>Beginning with nodal PTCLs, up to 60–100% of angioimmunoblastic T-cell lymphoma (AITL) and up to 40% of PTCL not otherwise specified (PTCL-NOS) demonstrate surface markers of follicular helper T (TFH) cells<sup><a href="#ref-4">4</a>–<a href="#ref-7">7</a></sup> and have common genetic features, such as <i>RHOA</i>, <i>TET2</i>, <i>DNMT3A</i>, and <i>IDH</i><sup><a href="#ref-8">8</a>–<a href="#ref-11">11</a></sup>. Two provisional entities have been introduced: follicular T-cell lymphoma and nodal peripheral T-cell lymphoma with the TFH phenotype. These entities can be diagnosed when their neoplastic cells express at least two or three TFH markers but do not display the clinicopathologic features of AITL, which would have been diagnosed as PTCL-NOS according to the 2008 World Health Organization classification. AITL and these two new entities are now categorized as nodal T-cell lymphoma with the TFH phenotype.</p><p class="" id=d4678e231>By definition, the PTCL-NOS designation encompasses all PTCLs lacking specific features that would allow categorization within any of the better-defined subtypes of PTCL, resulting in heterogeneity of this entity. A recent gene expression profiling study demonstrated that PTCL-NOS can be classified into two molecular groups according to the overexpression of either <i>GATA3</i> or <i>TBX21</i><sup><a href="#ref-12">12</a></sup>, and the <i>GATA3</i> subset shows inferior outcomes. However, as this study has not been applied in routine practice, the results have not led to the description of new entities.</p><p class="" id=d4678e246>ALK-negative anaplastic large-cell lymphoma (ALCL), which was a provisional entity in the 2008 classifications, has become a definite entity. This CD30-expressing neoplasm is not distinguishable from its ALK-positive counterpart on morphologic grounds, except for the absence of ALK expression. While the prognosis of ALK-negative ALCL is known to be less favorable<sup><a href="#ref-13">13</a></sup>, the five-year survival rate is comparable to that of ALK-positive ALC when <i>DUSP22</i> rearrangements are found<sup><a href="#ref-14">14</a></sup>. After first being described in 1997<sup><a href="#ref-15">15</a></sup>, breast implant-associated ALCL emerged as a distinct clinicopathologic entity, and it was proposed as a new entity in the 2016 classifications. All reported cases are ALK-negative, and the tumor is more frequently confined to the fibrous capsule. These cases show indolent clinical courses and respond well to implant removal and resection of the tumor. However, when the tumor presents with a mass discernible by radiologic or gross pathologic examination, it might be associated with a more aggressive clinical course<sup><a href="#ref-16">16</a>,<a href="#ref-17">17</a></sup>.</p><p class="" id=d4678e271>Major changes in extranodal PTCL cases have emerged from diseases that occur in the gastrointestinal (GI) tract. Enteropathy-associated T-cell lymphoma (EATL) is composed of two subtypes; type I EATL usually occurs following long-standing celiac disease (CD), showing large pleomorphic cells within an inflammatory background, and type II EATL occurs without antecedent CD, showing small, monotonous cells with epitheliotropism. In the 2016 classifications, diagnosis of EATL is to be used only for what was formerly type I EATL. Type II EATL has changed its name to monomorphic epitheliotropic intestinal T-cell lymphoma; it has been proposed as a new entity on the basis of its histologic, genetic, and molecular differences<sup><a href="#ref-18">18</a>–<a href="#ref-20">20</a></sup>. Whereas these two highly aggressive diseases show transmural growth, which often leads to GI bleeding or perforation, there is another one that grows superficially along the GI mucosa. Indolent T-cell lymphoproliferative disorder of the GI tract is a new provisional entity that usually presents with chronic diarrhea, weight loss, and malnutrition, mimicking the symptoms of inflammatory bowel disease<sup><a href="#ref-21">21</a></sup>. The course of this disease is known to be indolent, although some cases of transformation have been reported<sup><a href="#ref-22">22</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d4678e292>Current standard of care: conventional chemotherapy</h2><p class="" id=d4678e295>Anthracycline-containing regimens such as a combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP plus etoposide (CHOEP) are recommended as the front-line treatments for PTCLs<sup><a href="#ref-23">23</a>,<a href="#ref-24">24</a></sup>. Although clinical outcomes for these regimens vary according to histologic subtype, complete response (CR) rates range from 30% to 70%, and five-year overall survival (OS) rates range from 20% to 60%. Except in several small subsets, such as patients with ALK-positive ALCL or those with a low international prognostic index, the use of anthracycline-containing regimens failed to improve clinical outcomes<sup><a href="#ref-25">25</a>–<a href="#ref-27">27</a></sup>. Owing to the lack of efficacy of conventional CHOP, more intensive anthracycline-based regimens have been tried<sup><a href="#ref-28">28</a>–<a href="#ref-32">32</a></sup>; however, given limitations of small numbers of patients, intractable toxicities, and unfavorable results, none is considered a standard option. CHOP-14 or CHOEP can still be considered in select patients<sup><a href="#ref-33">33</a>,<a href="#ref-34">34</a></sup>.</p><p class="" id=d4678e326>Various combinations of several non-anthracycline drugs have been evaluated in front-line settings. In the S0350 trial, a combination of cisplatin, etoposide, gemcitabine, and solu-medrol (PEGS) was tried in 26 patients with newly diagnosed PTCL<sup><a href="#ref-35">35</a></sup>. The two-year progression-free survival (PFS) rate was 14%, and the two-year OS rate was 36%, which seemed to be no better than those of conventional combinations. Gemcitabine and etoposide were added to CHOP in 26 patients with newly diagnosed PTCL and this resulted in a CR rate of 62% and a median 215 days of event-free survival<sup><a href="#ref-36">36</a></sup>. An Italian group reported outcomes of biweekly administration of six cycles of gemcitabine, ifosfamide, and oxaliplatin in 21 patients with high-risk PTCL. The CR rate was 67%, and the five-year event-free survival rate was 49%. In a recent report from the randomized phase II study of the UK group using the combination of gemcitabine, cisplatin, and methylprednisolone (GEM-P), objective response rates (ORRs) were 57.1% for the CHOP arm and 43.2% for the experimental arm<sup><a href="#ref-37">37</a></sup>. Although grade 3–4 neutropenia or febrile neutropenia was more common in the CHOP arm, there was no difference in the two-year OS rate (53.1% versus 64.7%) or PFS rate (36.0% versus 39.0%). Outcomes of the recent trials for front-line treatment are summarized in <a href="#T1">Table 1</a>.</p><div class="table-wrap panel clearfix"><a name=T1 class=n-a></a><div class=caption><h3>Table 1. Summary of the recent trials of front-line treatment for peripheral T-cell lymphoma.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d4678e355 class=n-a></a><thead><a name=d4678e357 class=n-a></a><tr><a name=d4678e359 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d4678e361 class=n-a></a>Regimens</th><th align=left colspan=1 rowspan=1 valign=top><a name=d4678e364 class=n-a></a>Phase</th><th align=left colspan=1 rowspan=1 valign=top><a name=d4678e367 class=n-a></a>Total<br class=br>accrual</th><th align=left colspan=1 rowspan=1 valign=top><a name=d4678e372 class=n-a></a>CR/PR<br class=br>rates</th><th align=left colspan=1 rowspan=1 valign=top><a name=d4678e377 class=n-a></a>Survival<br class=br>outcomes</th><th align=left colspan=1 rowspan=1 valign=top><a name=d4678e383 class=n-a></a>Grade 3–4 toxicities</th></tr></thead><tbody><a name=d4678e388 class=n-a></a><tr><a name=d4678e390 class=n-a></a><td align=left colspan=6 rowspan=1><a name=d4678e392 class=n-a></a>CHOP-based combinations</td></tr><tr><a name=d4678e396 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d4678e398 class=n-a></a>Everolimus + CHOP<sup><a href="#ref-123">123</a></sup></td><td colspan=1 rowspan=1 valign=top><a name=d4678e404 class=n-a></a>II</td><td colspan=1 rowspan=1 valign=top><a name=d4678e407 class=n-a></a>30</td><td colspan=1 rowspan=1 valign=top><a name=d4678e410 class=n-a></a>57%/33%</td><td colspan=1 rowspan=1 valign=top><a name=d4678e413 class=n-a></a>2-year PFS: 33%<br class=br>2-year OS: 70%</td><td colspan=1 rowspan=1 valign=top><a name=d4678e419 class=n-a></a>Neutropenia: 80%<br class=br>Thrombocytopenia: 60%</td></tr><tr><a name=d4678e425 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d4678e427 class=n-a></a>Bortezomib + CHOP<sup><a href="#ref-114">114</a></sup></td><td colspan=1 rowspan=1 valign=top><a name=d4678e433 class=n-a></a>II</td><td colspan=1 rowspan=1 valign=top><a name=d4678e436 class=n-a></a>46</td><td colspan=1 rowspan=1 valign=top><a name=d4678e439 class=n-a></a>65%/9%</td><td colspan=1 rowspan=1 valign=top><a name=d4678e442 class=n-a></a>2-year PFS: 37%<br class=br>2-year OS: 52%</td><td colspan=1 rowspan=1 valign=top><a name=d4678e448 class=n-a></a>Neutropenia: 41%</td></tr><tr><a name=d4678e452 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d4678e454 class=n-a></a>Romidepsin + CHOP<sup><a href="#ref-65">65</a></sup></td><td colspan=1 rowspan=1 valign=top><a name=d4678e460 class=n-a></a>Ib/II</td><td colspan=1 rowspan=1 valign=top><a name=d4678e463 class=n-a></a>37</td><td colspan=1 rowspan=1 valign=top><a name=d4678e466 class=n-a></a>51%/17%</td><td colspan=1 rowspan=1 valign=top><a name=d4678e469 class=n-a></a>30-months PFS: 41%<br class=br>30-months OS: 71%</td><td colspan=1 rowspan=1 valign=top><a name=d4678e475 class=n-a></a>Neutropenia: 89%<br class=br>Thrombocytopenia: 78%</td></tr><tr><a name=d4678e481 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d4678e483 class=n-a></a>Belinostat + CHOP<sup><a href="#ref-100">100</a></sup></td><td colspan=1 rowspan=1 valign=top><a name=d4678e489 class=n-a></a>Ib</td><td colspan=1 rowspan=1 valign=top><a name=d4678e492 class=n-a></a>23</td><td colspan=1 rowspan=1 valign=top><a name=d4678e495 class=n-a></a>72%/17%</td><td colspan=1 rowspan=1 valign=top><a name=d4678e498 class=n-a></a>Not reported</td><td colspan=1 rowspan=1 valign=top><a name=d4678e502 class=n-a></a>Neutropenia: 26%<br class=br>Anemia: 22%</td></tr><tr><a name=d4678e509 class=n-a></a><td align=left colspan=6 rowspan=1><a name=d4678e511 class=n-a></a>Non-anthracycline combinations</td></tr><tr><a name=d4678e515 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d4678e517 class=n-a></a>Cyclophosphamide, etoposide, vincristine,<br class=br>prednisone alternating with pralatrexate<sup><a href="#ref-80">80</a></sup></td><td colspan=1 rowspan=1 valign=top><a name=d4678e525 class=n-a></a>II</td><td colspan=1 rowspan=1 valign=top><a name=d4678e528 class=n-a></a>33</td><td colspan=1 rowspan=1 valign=top><a name=d4678e531 class=n-a></a>52%/18%</td><td colspan=1 rowspan=1 valign=top><a name=d4678e534 class=n-a></a>2-year PFS: 39%<br class=br>2-year OS: 60%</td><td colspan=1 rowspan=1><a name=d4678e540 class=n-a></a></td></tr><tr><a name=d4678e543 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d4678e545 class=n-a></a>Gemcitabine, etoposide, cisplatin,<br class=br>methylprednisolone<sup><a href="#ref-35">35</a></sup></td><td colspan=1 rowspan=1 valign=top><a name=d4678e553 class=n-a></a>II</td><td colspan=1 rowspan=1 valign=top><a name=d4678e556 class=n-a></a>26</td><td colspan=1 rowspan=1 valign=top><a name=d4678e559 class=n-a></a>23%/15%</td><td colspan=1 rowspan=1 valign=top><a name=d4678e562 class=n-a></a>2-year PFS: 14%<br class=br>2-year OS: 36%</td><td colspan=1 rowspan=1 valign=top><a name=d4678e568 class=n-a></a>Neutropenia: 45%<br class=br>Anemia: 24%</td></tr><tr><a name=d4678e574 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d4678e576 class=n-a></a>Gemcitabine, cisplatin,<br class=br>methylprednisolone<sup><a href="#ref-37">37</a></sup></td><td colspan=1 rowspan=1 valign=top><a name=d4678e584 class=n-a></a>II</td><td colspan=1 rowspan=1 valign=top><a name=d4678e587 class=n-a></a>44</td><td colspan=1 rowspan=1 valign=top><a name=d4678e590 class=n-a></a>43%/not<br class=br>reported</td><td colspan=1 rowspan=1 valign=top><a name=d4678e595 class=n-a></a>2-year PFS: 39%<br class=br>2-year OS: 65%</td><td colspan=1 rowspan=1><a name=d4678e601 class=n-a></a></td></tr><tr><a name=d4678e604 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d4678e606 class=n-a></a>Gemcitabine, cisplatin, prednisone,<br class=br>thalidomide<sup><a href="#ref-111">111</a></sup></td><td colspan=1 rowspan=1 valign=top><a name=d4678e614 class=n-a></a>II</td><td colspan=1 rowspan=1 valign=top><a name=d4678e617 class=n-a></a>52</td><td colspan=1 rowspan=1 valign=top><a name=d4678e620 class=n-a></a>52%/15%</td><td colspan=1 rowspan=1 valign=top><a name=d4678e623 class=n-a></a>2-year PFS: 57%<br class=br>2-year OS: 71%</td><td colspan=1 rowspan=1 valign=top><a name=d4678e629 class=n-a></a>Myelosuppression: 44%</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d4678e637 class=n-a></a><p id=d4678e639> CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CR, complete response; OS, overall survival; PFS, progression-free survival; PR, partial response.</p></div></div></div><p class="" id=d4678e645>Collectively, although there is limited evidence that CHOP or its variants improve the prognosis of patients with PTCL, there is also little evidence that a certain non-anthracycline combination can replace CHOP. A randomized phase II study is under way to compare a combination of ifosfamide, carboplatin, and etoposide (ICE) and dexamethasone with CHOP (NCT02445404).</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d4678e651>Current standard of care: consolidation therapy</h2><p class="" id=d4678e654>Except for ALK-positive ALCLs, which show favorable outcomes with chemotherapy alone, current guidelines recommend consolidative autologous stem cell transplantation (ASCT) in patients with chemosensitive PTCL<sup><a href="#ref-23">23</a>,<a href="#ref-24">24</a></sup>. However, this recommendation was not established based on prospective randomized trials.</p><p class="" id=d4678e664>In a report by Reimer <i>et al</i>., 83 patients with PTCL received four to six cycles of CHOP, and for patients in partial response (PR) or CR at the end of induction, ASCT was performed<sup><a href="#ref-38">38</a></sup>. Fifty-five patients advanced to ASCT, and the three-year OS for patients who underwent ASCT was 71%. In the NLG-T-01 trial, 115 out of 160 patients with PTCL underwent ASCT after induction treatment of CHOEP-14 or CHOP-14<sup><a href="#ref-39">39</a></sup>. The 5-year PFS and OS rates were 44% and 51%, respectively, and the recently announced follow-up data revealed that the 10-year PFS and OS rates were 38% and 41%, respectively<sup><a href="#ref-40">40</a></sup>. Although it appears that prolonged survival can be achieved by ASCT, it should be noted that approximately 30% of patients are unable to receive it and this is mostly due to early progression. Several studies have compared the efficacy of front-line allogeneic stem cell transplantation (alloSCT) with ASCT<sup><a href="#ref-41">41</a>,<a href="#ref-42">42</a></sup>; however, the outcomes of alloSCT were not significantly different from those of ASCT. Taken together, these data suggest that ASCT should be considered as the first treatment in patients with chemosensitive PTCL.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d4678e692>Current standard of care: relapsed or refractory peripheral T-cell lymphoma</h2><p class="" id=d4678e695>Up to 20–30% of patients fail to achieve an initial response, and even after ASCT, over 50% will experience relapsed disease<sup><a href="#ref-38">38</a>,<a href="#ref-39">39</a></sup>. For those who have relapsed or refractory PTCL (rrPTCL), salvage chemotherapy with or without subsequent consolidation treatment can produce long-term remission. However, owing to refractoriness of the disease, overall outcomes remain poor<sup><a href="#ref-43">43</a></sup>. Several novel agents are actively being investigated in patients with rrPTCL. The major clinical findings of the studies with novel agents are summarized in <a href="#T2">Table 2</a>.</p><div class="table-wrap panel clearfix"><a name=T2 class=n-a></a><div class=caption><h3>Table 2. Selected studies of novel agents in the treatment of relapsed/refractory peripheral T-cell lymphomas.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d4678e723 class=n-a></a><thead><a name=d4678e725 class=n-a></a><tr><a name=d4678e727 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d4678e729 class=n-a></a>Agent</th><th align=left colspan=1 rowspan=1 valign=top><a name=d4678e732 class=n-a></a>Phase</th><th align=left colspan=1 rowspan=1 valign=top><a name=d4678e735 class=n-a></a>Total<br class=br>accrual</th><th align=left colspan=1 rowspan=1 valign=top><a name=d4678e740 class=n-a></a>CR/PR<br class=br>rates</th><th align=left colspan=1 rowspan=1 valign=top><a name=d4678e745 class=n-a></a>Survival outcomes</th><th align=left colspan=1 rowspan=1 valign=top><a name=d4678e749 class=n-a></a>Major grade 3–4 toxicities</th></tr></thead><tbody><a name=d4678e754 class=n-a></a><tr><a name=d4678e756 class=n-a></a><td align=left colspan=6 rowspan=1><a name=d4678e758 class=n-a></a>Monoclonal antibodies</td></tr><tr><a name=d4678e762 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d4678e764 class=n-a></a>Brentuximab vedotin</td><td colspan=1 rowspan=1 valign=top><a name=d4678e767 class=n-a></a>II<sup><a href="#ref-52">52</a></sup></td><td colspan=1 rowspan=1 valign=top><a name=d4678e773 class=n-a></a>58 (ALCL)</td><td colspan=1 rowspan=1 valign=top><a name=d4678e776 class=n-a></a>57%/29%</td><td colspan=1 rowspan=1 valign=top><a name=d4678e779 class=n-a></a>1-year OS rate: 70%<br class=br>4-year OS rate: 64%<br class=br>5-year OS rate: 60%</td><td colspan=1 rowspan=1 valign=top><a name=d4678e787 class=n-a></a>Peripheral sensory neuropathy,<br class=br>neutropenia, thrombocytopenia</td></tr><tr><a name=d4678e793 class=n-a></a><td colspan=1 rowspan=1><a name=d4678e795 class=n-a></a></td><td colspan=1 rowspan=1 valign=top><a name=d4678e797 class=n-a></a>II<sup><a href="#ref-58">58</a></sup></td><td colspan=1 rowspan=1 valign=top><a name=d4678e803 class=n-a></a>35<br class=br>(non-ALCL)</td><td colspan=1 rowspan=1 valign=top><a name=d4678e808 class=n-a></a>24%/18%</td><td colspan=1 rowspan=1 valign=top><a name=d4678e811 class=n-a></a>Median PFS: 2.6 months</td><td colspan=1 rowspan=1 valign=top><a name=d4678e815 class=n-a></a>Peripheral sensory neuropathy,<br class=br>neutropenia, hyperkalemia</td></tr><tr><a name=d4678e821 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d4678e823 class=n-a></a>Mogamulizumab</td><td colspan=1 rowspan=1 valign=top><a name=d4678e826 class=n-a></a>II<sup><a href="#ref-64">64</a></sup></td><td colspan=1 rowspan=1 valign=top><a name=d4678e832 class=n-a></a>38</td><td colspan=1 rowspan=1 valign=top><a name=d4678e835 class=n-a></a>14%/19%</td><td colspan=1 rowspan=1 valign=top><a name=d4678e838 class=n-a></a>Median PFS: 3.0 months</td><td colspan=1 rowspan=1 valign=top><a name=d4678e842 class=n-a></a>Lymphocytopenia, neutropenia</td></tr><tr><a name=d4678e846 class=n-a></a><td align=left colspan=6 rowspan=1><a name=d4678e848 class=n-a></a>Anti-folates</td></tr><tr><a name=d4678e853 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d4678e855 class=n-a></a>Pralatrexate</td><td colspan=1 rowspan=1 valign=top><a name=d4678e858 class=n-a></a>II<sup><a href="#ref-76">76</a></sup></td><td colspan=1 rowspan=1 valign=top><a name=d4678e864 class=n-a></a>111</td><td colspan=1 rowspan=1 valign=top><a name=d4678e867 class=n-a></a>11%/18%</td><td colspan=1 rowspan=1 valign=top><a name=d4678e870 class=n-a></a>Median PFS: 3.5 months<br class=br>Median OS: 14.5 months</td><td colspan=1 rowspan=1 valign=top><a name=d4678e876 class=n-a></a>Neutropenia, thrombocytopenia,<br class=br>mucositis</td></tr><tr><a name=d4678e882 class=n-a></a><td align=left colspan=6 rowspan=1><a name=d4678e884 class=n-a></a>Histone deacetylase inhibitors</td></tr><tr><a name=d4678e888 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d4678e890 class=n-a></a>Romidepsin</td><td colspan=1 rowspan=1 valign=top><a name=d4678e893 class=n-a></a>II<sup><a href="#ref-89">89</a></sup></td><td colspan=1 rowspan=1 valign=top><a name=d4678e899 class=n-a></a>131</td><td colspan=1 rowspan=1 valign=top><a name=d4678e902 class=n-a></a>15%/11%</td><td colspan=1 rowspan=1 valign=top><a name=d4678e905 class=n-a></a>Median PFS: 4.0 months<br class=br>Median OS: 11.3 months</td><td colspan=1 rowspan=1 valign=top><a name=d4678e911 class=n-a></a>Neutropenia, thrombocytopenia</td></tr><tr><a name=d4678e915 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d4678e917 class=n-a></a>Romidepsin + gemcitabine</td><td colspan=1 rowspan=1 valign=top><a name=d4678e920 class=n-a></a>II<sup><a href="#ref-94">94</a></sup></td><td colspan=1 rowspan=1 valign=top><a name=d4678e926 class=n-a></a>20</td><td colspan=1 rowspan=1 valign=top><a name=d4678e929 class=n-a></a>15%/15%</td><td colspan=1 rowspan=1 valign=top><a name=d4678e932 class=n-a></a>2-year PFS: 11%<br class=br>2-year OS: 50%</td><td colspan=1 rowspan=1 valign=top><a name=d4678e938 class=n-a></a>Neutropenia, thrombocytopenia,<br class=br>anemia</td></tr><tr><a name=d4678e944 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d4678e946 class=n-a></a>Belinostat</td><td colspan=1 rowspan=1 valign=top><a name=d4678e949 class=n-a></a>II<sup><a href="#ref-98">98</a></sup></td><td colspan=1 rowspan=1 valign=top><a name=d4678e955 class=n-a></a>120</td><td colspan=1 rowspan=1 valign=top><a name=d4678e958 class=n-a></a>11%/15%</td><td colspan=1 rowspan=1 valign=top><a name=d4678e961 class=n-a></a>Median PFS: 1.6 months<br class=br>Median OS: 7.9 months</td><td colspan=1 rowspan=1 valign=top><a name=d4678e967 class=n-a></a>Neutropenia, fatigue</td></tr><tr><a name=d4678e971 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d4678e973 class=n-a></a>Chidamide</td><td colspan=1 rowspan=1 valign=top><a name=d4678e976 class=n-a></a>II<sup><a href="#ref-102">102</a></sup></td><td colspan=1 rowspan=1 valign=top><a name=d4678e982 class=n-a></a>83</td><td colspan=1 rowspan=1 valign=top><a name=d4678e985 class=n-a></a>14%/15%</td><td colspan=1 rowspan=1 valign=top><a name=d4678e988 class=n-a></a>Median PFS: 2.1 months<br class=br>Median OS: 21.4 months</td><td colspan=1 rowspan=1 valign=top><a name=d4678e994 class=n-a></a>Neutropenia, thrombocytopenia</td></tr><tr><a name=d4678e999 class=n-a></a><td align=left colspan=6 rowspan=1><a name=d4678e1001 class=n-a></a>Immunomodulatory drugs</td></tr><tr><a name=d4678e1005 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d4678e1007 class=n-a></a>Lenalidomide</td><td colspan=1 rowspan=1 valign=top><a name=d4678e1010 class=n-a></a>II<sup><a href="#ref-108">108</a></sup></td><td colspan=1 rowspan=1 valign=top><a name=d4678e1016 class=n-a></a>54</td><td colspan=1 rowspan=1 valign=top><a name=d4678e1019 class=n-a></a>11%/11%</td><td colspan=1 rowspan=1 valign=top><a name=d4678e1022 class=n-a></a>Median PFS: 1.9 months</td><td colspan=1 rowspan=1 valign=top><a name=d4678e1026 class=n-a></a>Neutropenia, thrombocytopenia,<br class=br>pneumonia, gastrointestinal disorder</td></tr><tr><a name=d4678e1032 class=n-a></a><td colspan=1 rowspan=1><a name=d4678e1034 class=n-a></a></td><td colspan=1 rowspan=1 valign=top><a name=d4678e1036 class=n-a></a>II<sup><a href="#ref-109">109</a></sup></td><td colspan=1 rowspan=1 valign=top><a name=d4678e1042 class=n-a></a>40</td><td colspan=1 rowspan=1 valign=top><a name=d4678e1045 class=n-a></a>8%/18%</td><td colspan=1 rowspan=1 valign=top><a name=d4678e1048 class=n-a></a>Median PFS: 4 months<br class=br>Median OS: 12 months</td><td colspan=1 rowspan=1 valign=top><a name=d4678e1054 class=n-a></a>Neutropenia, pain, dyspnea</td></tr><tr><a name=d4678e1058 class=n-a></a><td align=left colspan=6 rowspan=1><a name=d4678e1060 class=n-a></a>Inhibitors of PI3K/mTOR pathways</td></tr><tr><a name=d4678e1064 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d4678e1066 class=n-a></a>Duvelisib</td><td colspan=1 rowspan=1 valign=top><a name=d4678e1069 class=n-a></a>I<sup><a href="#ref-117">117</a></sup></td><td colspan=1 rowspan=1 valign=top><a name=d4678e1075 class=n-a></a>15</td><td colspan=1 rowspan=1 valign=top><a name=d4678e1078 class=n-a></a>13%/33%</td><td colspan=1 rowspan=1 valign=top><a name=d4678e1081 class=n-a></a>Median OS: 36.4 weeks</td><td colspan=1 rowspan=1 valign=top><a name=d4678e1085 class=n-a></a>Hepatitis, rash, neutropenia</td></tr><tr><a name=d4678e1089 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d4678e1091 class=n-a></a>Copanlisib</td><td colspan=1 rowspan=1 valign=top><a name=d4678e1094 class=n-a></a>II<sup><a href="#ref-119">119</a></sup></td><td colspan=1 rowspan=1 valign=top><a name=d4678e1100 class=n-a></a>17</td><td colspan=1 rowspan=1 valign=top><a name=d4678e1103 class=n-a></a>14%/7%</td><td colspan=1 rowspan=1 valign=top><a name=d4678e1106 class=n-a></a>Not reported</td><td colspan=1 rowspan=1 valign=top><a name=d4678e1110 class=n-a></a>Hypertension, neutropenia,<br class=br>hyperglycemia</td></tr><tr><a name=d4678e1117 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d4678e1119 class=n-a></a>Everolimus</td><td colspan=1 rowspan=1 valign=top><a name=d4678e1122 class=n-a></a>II<sup><a href="#ref-124">124</a></sup></td><td colspan=1 rowspan=1 valign=top><a name=d4678e1128 class=n-a></a>16</td><td colspan=1 rowspan=1 valign=top><a name=d4678e1131 class=n-a></a>6%/38%</td><td colspan=1 rowspan=1 valign=top><a name=d4678e1134 class=n-a></a>Median PFS: 4.1 months<br class=br>Median OS: 10.2 months</td><td colspan=1 rowspan=1 valign=top><a name=d4678e1140 class=n-a></a>Neutropenia, thrombocytopenia,<br class=br>anemia, hyperglycemia</td></tr><tr><a name=d4678e1146 class=n-a></a><td align=left colspan=6 rowspan=1><a name=d4678e1148 class=n-a></a>Alternative agents</td></tr><tr><a name=d4678e1152 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d4678e1154 class=n-a></a>Bendamustine</td><td colspan=1 rowspan=1 valign=top><a name=d4678e1157 class=n-a></a>II<sup><a href="#ref-125">125</a></sup></td><td colspan=1 rowspan=1 valign=top><a name=d4678e1163 class=n-a></a>60</td><td colspan=1 rowspan=1 valign=top><a name=d4678e1166 class=n-a></a>28%/22%</td><td colspan=1 rowspan=1 valign=top><a name=d4678e1169 class=n-a></a>Median PFS: 3.6 months<br class=br>Median OS: 6.2 months</td><td colspan=1 rowspan=1 valign=top><a name=d4678e1175 class=n-a></a>Neutropenia, thrombocytopenia,<br class=br>infection</td></tr><tr><a name=d4678e1181 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d4678e1183 class=n-a></a>Bendamustine + carboplatin<br class=br>+ dexamethasone</td><td colspan=1 rowspan=1 valign=top><a name=d4678e1188 class=n-a></a>II<sup><a href="#ref-126">126</a></sup></td><td colspan=1 rowspan=1 valign=top><a name=d4678e1194 class=n-a></a>30</td><td colspan=1 rowspan=1 valign=top><a name=d4678e1197 class=n-a></a>30%/25%</td><td colspan=1 rowspan=1 valign=top><a name=d4678e1200 class=n-a></a>Median PFS: 4.8 months</td><td colspan=1 rowspan=1 valign=top><a name=d4678e1204 class=n-a></a>Neutropenia, thrombocytopenia,<br class=br>anemia</td></tr><tr><a name=d4678e1210 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d4678e1212 class=n-a></a>Alisertib</td><td colspan=1 rowspan=1 valign=top><a name=d4678e1215 class=n-a></a>III<sup><a href="#ref-130">130</a></sup></td><td colspan=1 rowspan=1 valign=top><a name=d4678e1221 class=n-a></a>120</td><td colspan=1 rowspan=1 valign=top><a name=d4678e1224 class=n-a></a>16%/17%</td><td colspan=1 rowspan=1 valign=top><a name=d4678e1227 class=n-a></a>Median PFS: 3.7 months<br class=br>Median OS: 9.9 months</td><td colspan=1 rowspan=1 valign=top><a name=d4678e1233 class=n-a></a>Neutropenia, thrombocytopenia,<br class=br>anemia</td></tr><tr><a name=d4678e1239 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d4678e1241 class=n-a></a>Tipifarnib</td><td colspan=1 rowspan=1 valign=top><a name=d4678e1244 class=n-a></a>II<sup><a href="#ref-132">132</a></sup></td><td colspan=1 rowspan=1 valign=top><a name=d4678e1250 class=n-a></a>18</td><td colspan=1 rowspan=1 valign=top><a name=d4678e1253 class=n-a></a>0%/17%</td><td colspan=1 rowspan=1 valign=top><a name=d4678e1256 class=n-a></a>Not reported</td><td colspan=1 rowspan=1 valign=top><a name=d4678e1260 class=n-a></a>Neutropenia, thrombocytopenia</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d4678e1268 class=n-a></a><p id=d4678e1270> ALCL, anaplastic large-cell lymphoma; CR, complete response; OS, overall survival; PFS, progression-free survival; PR, partial response.</p></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d4678e1280>Monoclonal antibodies</h2><div class=section><a name=d4678e1283 class=n-a></a><h3 class=section-title>Alemtuzumab</h3><p class="" id=d4678e1288>Alemtuzumab is a humanized monoclonal antibody (mAb) against CD52. As a salvage treatment, it has been evaluated either as monotherapy<sup><a href="#ref-44">44</a></sup> or as combination therapy with various backbones<sup><a href="#ref-45">45</a>–<a href="#ref-47">47</a></sup>. Although high CR rates were observed (36–54%), severe opportunistic infections caused concerns. Combinations of alemtuzumab with conventional three-weekly CHOP<sup><a href="#ref-48">48</a></sup>, two-weekly CHOP<sup><a href="#ref-49">49</a></sup>, four-weekly CHOP<sup><a href="#ref-50">50</a></sup>, and CHOEP-14<sup><a href="#ref-51">51</a></sup> have been assessed in patients with newly diagnosed PTCL. Again, high CR rates (59–71%) were accompanied by profound hematologic toxicity and opportunistic infection. Two international phase III trials are ongoing to evaluate the role of alemtuzumab when added to the first four (out of six) cycles of CHOP-14 (NCT00646854 and NCT00725231).</p></div><div class=section><a name=d4678e1320 class=n-a></a><h3 class=section-title>Brentuximab vedotin</h3><p class="" id=d4678e1325>Brentuximab vedotin (BV) is an antibody-drug conjugate comprising an anti-CD30 mAb conjugated to an anti-microtubule agent, monomethyl auristatin E. As CD30 is typically expressed in Hodgkin’s lymphoma and ALCL, most major findings have been achieved in those diseases. In a pivotal phase II trial, patients with relapsed or refractory systemic ALCL received BV 1.8 mg/kg every three weeks for up to 16 cycles<sup><a href="#ref-52">52</a></sup>. Among 58 patients, the ORR was 86% (n = 50) and 33 patients (57%) achieved CR. The four- and five-year survival data demonstrated that long-term remission can be achieved by BV treatment<sup><a href="#ref-53">53</a>,<a href="#ref-54">54</a></sup>. For PTCLs other than ALCL, the rate of CD30 positivity varies according to subtype and report<sup><a href="#ref-14">14</a>,<a href="#ref-55">55</a>–<a href="#ref-57">57</a></sup>. During a phase II trial in which 35 patients with relapsed or refractory CD30-positive PTCL (22 PTCL-NOS and 13 AITL) received BV at a dose of 1.8 mg/kg every three weeks, the ORR was 41% (95% confidence interval 24.6–59.3), and the PFS of patients with AITL was longer than that of the patients with PTCL-NOS (6.7 versus 1.6 months)<sup><a href="#ref-58">58</a></sup>. Several BV-based combinations have also been evaluated. In a phase I trial, 39 treatment-naïve patients with a diagnosis of CD30-positive PTCL were recruited to receive either sequential treatment (two cycles of BV, six cycles of CHOP, and eight cycles of BV) or combination treatment (six cycles of BV in combination with vincristine-omitted CHP and 10 cycles of BV)<sup><a href="#ref-59">59</a></sup>. There were seven patients with non-ALCL PTCL—two PTCL-NOS, two AITL, two adult T-cell leukemia/lymphoma (ATLL), and one EATL—they were all allocated to a combination arm for which a CR rate of 100% was noted. A subsequent four-year follow-up analysis revealed that six out of seven of them were still alive<sup><a href="#ref-60">60</a></sup>. Based on these favorable outcomes, a randomized phase III trial is ongoing to compare BV-CHP versus CHOP in patients with CD30-positive PTCL (ECHELON-2 (A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas)) trial, NCT01777152).</p></div><div class=section><a name=d4678e1363 class=n-a></a><h3 class=section-title>Mogamulizumab</h3><p class="" id=d4678e1368>Mogamulizumab is a humanized mAb targeting the CC chemokine receptor 4 (CCR4), which is expressed in physiologic regulatory T cells. CCR4 is also expressed in nearly 90% of ATLL cases<sup><a href="#ref-61">61</a></sup> and in approximately 30–65% of patients with PTCLs<sup><a href="#ref-62">62</a>,<a href="#ref-63">63</a></sup>, and expression of CCR4 is associated with poor survival. In a Japanese phase II trial, 29 patients with CCR4-positive, relapsed PTCL were recruited to receive mogamulizumab at a dose of 1.0 mg/kg per week for eight weeks<sup><a href="#ref-64">64</a></sup>. Five CRs and PRs, which made up 34% of the ORR, were noted. Lymphopenia was the most frequent adverse event (grade 3–4, 73%), and 51% of patients experienced skin disorders of any grade. The degree of CCR4 expression was not correlated with the clinical response. However, in a European phase II trial, a lower ORR was noted<sup><a href="#ref-65">65</a></sup>. Of 35 patients with rrPTCL, only one CR and three PRs were noted, and the ORR was 11.4%. The lower ORR can be explained by the different setting (relapsed only versus relapsed or refractory patients), the poorer performance status of the European study population (0% versus 40% of patients were Eastern Cooperative Oncology Group performance status 2), or the lower dose intensity of the administration schedule (weekly administration for eight weeks versus weekly administration for four weeks followed by biweekly administration).</p></div><div class=section><a name=d4678e1391 class=n-a></a><h3 class=section-title>Immune checkpoint inhibitors</h3><p class="" id=d4678e1396>It has long been recognized that the tumor microenvironment plays important roles in lymphomagenesis, proliferation, and immune evasion<sup><a href="#ref-66">66</a>,<a href="#ref-67">67</a></sup>. In T-cell lymphoma, the microenvironment defines the tumor itself (such as in AITL), and many subtypes manifest strong tissue tropism (such as in CTCL or primary GI lymphomas).</p><p class="" id=d4678e1406>Given that PD-1 is expressed in a substantial portion of PTCL cases<sup><a href="#ref-68">68</a></sup> and that PD-L1 is frequently expressed in certain virus-associated lymphomas<sup><a href="#ref-69">69</a></sup>, this pathway is of major interest. Nivolumab is a fully human anti-PD1 mAb. In a phase I, dose-escalating study, a total of 81 patients with lymphoid malignancy (B-cell lymphoma 31, T-cell lymphoma 23, and multiple myeloma 27) received nivolumab at doses of 1 or 3 mg/kg every two weeks<sup><a href="#ref-70">70</a></sup>. Among five patients with PTCL, two PRs were observed, and the median PFS was 14 weeks. In the two responding patients with PTCL, a sustained duration of response (DoR) was observed. Several trials are ongoing to evaluate the role of this agent in patients with PTCL as a monotherapy (NCT03075553 and NCT02973113) or as combination therapy with BV (NCT0258163). Evaluation of pembrolizumab, another PD-1 mAb, in PTCL has been based on anecdote<sup><a href="#ref-71">71</a>,<a href="#ref-72">72</a></sup>, and two studies are under way for patients with rrPTCL (NCT03021057 and NCT02362997). In regard to mAbs targeting PD-L1 or PD-L2 or both, prospective studies with avelumab (NCT03046953) and durvalumab (NCT03161223 and NCT03011814) are taking place.</p><p class="" id=d4678e1428>Ipilimumab is a fully humanized mAb targeting cytotoxic T lymphocyte-associated protein 4 (CTLA-4). In a phase I study, nivolumab combined with ipilimumab was given at 3 mg/kg or 1 mg/kg every three weeks for four doses, and this was followed by nivolumab monotherapy every two weeks<sup><a href="#ref-73">73</a></sup>. Eleven patients with heavily pre-treated T-cell lymphoma were included, one PR and four standard deviations were noted, and one patient proceeded to alloSCT.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d4678e1439>Anti-folates</h2><p class="" id=d4678e1442>Anti-folates demonstrate anti-tumor efficacy by inhibiting dihydrofolate reductase, which converts dihydrofolate to tetrahydrofolate. Depletion of tetrahydrofolate disrupts the synthesis of pyrimidines and amino acids such as serine, glycine, and methionine<sup><a href="#ref-74">74</a></sup>.</p><div class=section><a name=d4678e1449 class=n-a></a><h3 class=section-title>Pralatrexate</h3><p class="" id=d4678e1454>In an early phase trial with pralatrexate, a higher CR was observed in patients with PTCL compared with those of B-cell lymphoma at the cost of significant mucositis<sup><a href="#ref-75">75</a></sup>. This toxicity was later found to be alleviated by the administration of vitamin B<sub>12</sub> and folic acid.</p><p class="" id=d4678e1464>In the PROPEL (Pralatrexate in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma) trial, a total of 111 patients with rrPTCL received pralatrexate at a dose of 30 mg/m<sup>2</sup> for six out of seven weeks along with vitamin B<sub>12</sub> and folic acid<sup><a href="#ref-76">76</a></sup>. Among 109 evaluable patients, 12 CRs (11%) and 20 PRs (18%) were noted. The median duration of response and the median OS were 10.1 and 14.5 months, respectively. The most common grade 3–4 toxicities were thrombocytopenia (32%), mucositis (22%), neutropenia (22%), and anemia (18%), but pralatrexate was well tolerated, as the overall dose intensity was 80%. In the Japanese trial with the same dose and schedule, nine (45%) out of 20 evaluable patients achieved an objective response, and grade 3–4 thrombocytopenia occurred in 40% of cases<sup><a href="#ref-77">77</a></sup>.</p><p class="" id=d4678e1481>Based on the synergism pralatrexate has shown in preclinical analyses<sup><a href="#ref-78">78</a>,<a href="#ref-79">79</a></sup>, several combinations with it have been evaluated. In a phase II trial, a front-line combination of cyclophosphamide, etoposide, vincristine, and prednisone (CEOP) alternating with pralatrexate was evaluated in 33 patients with untreated PTCL<sup><a href="#ref-80">80</a></sup>. Seventeen CRs (52%) and six PRs (18%) were achieved, and 15 patients received ASCT. The two-year PFS and OS rates were 39% and 60%, respectively, similar to outcomes with CHOP. Grade 3–4 anemia (27%), febrile neutropenia (18%), mucositis (18%), and thrombocytopenia (12%) occurred. In a phase I trial, pralatrexate followed by gemcitabine was administered in 34 patients with relapsed or refractory lymphoproliferative malignancies, among whom 11 patients with PTCL were included<sup><a href="#ref-81">81</a></sup>. Of the 33 patients who were evaluable for response, seven (21%) showed a partial response, and two of the seven had T-cell lymphoma. In another case series, five elderly patients with rrPTCL received weekly administration of pralatrexate (15 mg/m<sup>2</sup>) and bortezomib (1.3 mg/m<sup>2</sup>) for three out of four weeks until progression<sup><a href="#ref-82">82</a></sup>. One patient achieved CR after four cycles, which lasted over 12 months.</p><p class="" id=d4678e1510>Several pralatrexate-based combinations, including CHOP (NCT02594267), pembrolizumab plus decitabine (NCT03240211), romidepsin (NCT01947140), and durvalumab (NCT03161223), are under evaluation.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d4678e1517>Histone deacetylase inhibitors</h2><p class="" id=d4678e1520>Histone deacetylase (HDAC) inhibitors demonstrate anti-tumor efficacy by upregulating the expression of genes for cell cycle regulators, cell type-specific differentiation, and pro-apoptotic proteins<sup><a href="#ref-83">83</a>,<a href="#ref-84">84</a></sup>. Various classes of HDACs with clinical significance are expressed in patients with PTCL<sup><a href="#ref-85">85</a>,<a href="#ref-86">86</a></sup>. Two agents have been approved by the US Food and Drug Administration for treatment of PTCL: romidepsin (2011) and belinostat (2014).</p><div class=section><a name=d4678e1537 class=n-a></a><h3 class=section-title>Romidepsin</h3><p class="" id=d4678e1542>Romidepsin is a cyclic tetrapeptide-derived class-I selective HDAC inhibitor. After favorable outcomes were observed in an early phase trial<sup><a href="#ref-87">87</a></sup>, a phase II trial was carried out in 47 patients with rrPTCL<sup><a href="#ref-88">88</a></sup>. Romidepsin was administered in three out of four weeks with a starting dose of 14 mg/m<sup>2</sup>, which could be escalated up to 17.5 mg/m<sup>2</sup> in the absence of toxicity. Among 45 evaluable patients, eight (18%) experienced CR and nine (20%) experienced PR. Thrombocytopenia was observed in 47% of patients; of note, Epstein-Barr virus (EBV)-associated lymphoproliferative disorder emerged in two patients. In the pivotal phase II trial<sup><a href="#ref-89">89</a></sup>, a total of 131 patients with rrPTCL received romidepsin at a dose of 14 mg/m<sup>2</sup> for three out of four weeks. Among 130 evaluable patients, 19 (15%) experienced CR and 14 (10%) experienced PR. Rapid responses were observed, and median time to response was 1.8 months and median time to CR was 3.7 months. In the 19 patients who achieved CR, the median PFS was 18 months. Grade 3–4 thrombocytopenia and neutropenia occurred in 23% and 18% of cases, respectively. The updated efficacy data demonstrated that, of the 19 patients who achieved CR, 10 had long-term (at least 12 months) responses<sup><a href="#ref-90">90</a></sup>. In the phase II part of the Japanese trial, 40 patients with rrPTCL received 14 mg/m<sup>2</sup> of romidepsin<sup><a href="#ref-91">91</a></sup>. The CR rate was 25% (10/40), and the PR rate was 18% (7/40). Treatment-related adverse events led to discontinuation of romidepsin in 26% of patients.</p><p class="" id=d4678e1578>Interestingly, an <i>in vivo</i> and <i>in vitro</i> study has suggested a role for romidepsin in the treatment of EBV-associated cancer, where it can induce the EBV lytic cycle<sup><a href="#ref-92">92</a></sup>. In a Korean pilot study, however, three out of five patients with NK/T-cell lymphoma experienced EBV reactivation after romidepsin treatment<sup><a href="#ref-93">93</a></sup>. This finding is consistent with the findings from the aforementioned two cases of EBV-associated lymphoproliferative disorder<sup><a href="#ref-88">88</a></sup>. Thus, EBV-reactivation should be taken into account when using romidepsin to treat EBV-associated lymphoma.</p><p class="" id=d4678e1599>Several romidepsin-based regimens are being evaluated. In the front-line setting, romidepsin plus CHOP was administered in 37 patients with PTCL<sup><a href="#ref-65">65</a></sup>. Although hematologic toxicities precluded the completion of the planned treatment in 18% of patients, the CR rate was 51%, the PR rate was 17%, and the OS rate at 30 months was 70.7%. Prospective trials with romidepsin plus CHOP (NCT01796002) or CHOEP-21 (NCT02223208) are ongoing.</p><p class="" id=d4678e1606>In the salvage setting, romidepsin at 12 mg/m<sup>2</sup> (days 1, 8, and 15) with gemcitabine at 800 mg/m<sup>2</sup> (days 1 and 15) up to six cycles, followed by romidepsin maintenance (at 14 mg/m<sup>2</sup>), was given to 20 patients with rrPTCL<sup><a href="#ref-94">94</a></sup>. The clinical outcomes of the combination were a little better than those with monotherapy; the CR rate and the ORR were 15% and 30%, respectively. Another phase I study of romidepsin, gemcitabine, dexamethasone, and cisplatin was carried out by a Canadian group<sup><a href="#ref-95">95</a></sup>, and of the 10 patients with PTCL, five responded. In addition, when romidepsin was added to ICE<sup><a href="#ref-96">96</a></sup>, the CR rate was 64% (9/14) and the ORR was 78% (11/14). However, grade 3–4 thrombocytopenia and neutropenia occurred in 95% and 84% of the cycles, respectively.</p></div><div class=section><a name=d4678e1632 class=n-a></a><h3 class=section-title>Belinostat</h3><p class="" id=d4678e1637>Belinostat is a hydroxamic acid-derived, pan-HDAC inhibitor that demonstrates high affinity for the class I and II HDACs. In an early phase II trial, 24 patients with rrPTCL received belinostat, the ORR was 25% (6/24), and two patients experienced CR<sup><a href="#ref-97">97</a></sup>. In the phase II BELIEF (A Multicenter, Open Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma) trial, 129 patients with rrPTCL were enrolled to receive belinostat at 1,000 mg/m<sup>2</sup> for five days every three weeks<sup><a href="#ref-98">98</a></sup>. Among 120 evaluable patients, 13 achieved CR (11%) and 18 achieved PR (15%), and the ORR was 26%. In patients with CR, the median DoR exceeded 29 months. A subtype analysis revealed that, among 22 patients with AITL, the ORR was 45% (four CRs and six PRs)<sup><a href="#ref-99">99</a></sup>. Most adverse events—nausea (42%), fatigue (37%), and pyrexia (35%)—were non-hematologic. Only 7% and 10% of patients experienced grade 3–4 thrombocytopenia and anemia, respectively.</p><p class="" id=d4678e1655>These favorable hematologic toxicities provided momentum for initiating the next combination trial. In a phase I trial, belinostat at a dose of 1,000 mg/m<sup>2</sup> for five days every three weeks was combined with CHOP for six cycles in 23 patients with untreated PTCL<sup><a href="#ref-100">100</a></sup>. The combination was well tolerated; 18 patients (78%) completed six cycles. Among 21 evaluable patients, the ORR was 86% (n = 18), and most patients comprising the ORR were CR (n = 14, 67%).</p></div><div class=section><a name=d4678e1666 class=n-a></a><h3 class=section-title>Chidamide</h3><p class="" id=d4678e1671>Chidamide is an orally administered benzamide class of HDAC that demonstrates selective inhibition of HDAC1, 2, 3, and 10<sup><a href="#ref-101">101</a></sup>. In a phase II trial, 83 patients with rrPTCL took 30 mg of chidamide twice weekly<sup><a href="#ref-102">102</a></sup>. Among 79 evaluable patients, 11 CRs (14%) and 12 PRs (15%) were noted, and the median time to response was 1.4 months and the median DoR was 9.9 months. Grade 3–4 thrombocytopenia occurred in 22% of patients, and neutropenia occurred in 11% of patients. On the basis of these results, the Chinese Food and Drug Administration approved the use of chidamide to treat rrPTCL in 2014. Subsequently, large-scale real-world data were recently released<sup><a href="#ref-103">103</a></sup>. Chidamide monotherapy resulted in an ORR of 39% (100/256) and a CR rate of 9% (27/256). Chidamide-based combination therapies demonstrated the highest ORR (51%, 65/127) and CR rate (12%, 15/127). In the monotherapy group, grade 3–4 thrombocytopenia occurred in 10.2% of cases and neutropenia occurred in 6.2% of cases. The real-world data demonstrated clinical outcomes similar to those of the phase II trial. Several trials with chidamide-based combinations (NCT02809573, NCT02987244, NCT02856997, and NCT03023358) are ongoing.</p></div><div class=section><a name=d4678e1688 class=n-a></a><h3 class=section-title>Other histone deacetylase inhibitors</h3><p class="" id=d4678e1693>Vorinostat is an orally administered benzamide HDAC inhibitor of class I–II. In a front-line setting, a combination of vorinostat plus CHOP demonstrated 79% and 81% of two-year PFS and OS rate, respectively<sup><a href="#ref-104">104</a></sup>. In a relapsed or refractory setting, a combination of vorinostat, lenalidomide, and dexamethasone (40 mg once daily) was explored<sup><a href="#ref-105">105</a></sup>, but the outcomes were not remarkable.</p><p class="" id=d4678e1704>Panobinostat is an orally administered pan-HDAC inhibitor. In a phase II study<sup><a href="#ref-106">106</a></sup>, 25 patients with rrPTCL or ENKTL received panobinostat at a dose of 20 mg three times a week and bortezomib at a dose of 1.3 mg/m<sup>2</sup>. The ORR was 43% (10/23), and the CR rate was 22% (5/23). Common treatment-related grade 3–4 toxicities were thrombocytopenia (68%), neutropenia (36%), and diarrhea (28%).</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d4678e1718>Immunomodulatory drugs</h2><p class="" id=d4678e1721>Lenalidomide shows anti-lymphoma efficacy through immune modulation of the microenvironment and anti-proliferative and anti-angiogenic mechanisms<sup><a href="#ref-107">107</a></sup>. Two trials have investigated single-agent lenalidomide for 21 out of 28 days in patients with rrPTCL<sup><a href="#ref-108">108</a>,<a href="#ref-109">109</a></sup>. The CR rate ranged from 8% to 30%, and the ORR ranged from 22% to 30%. A substantial portion of patients (26–35%) experienced toxicities and this led to treatment discontinuation. Outcomes in patients with AITL, compared with other subtypes, were unique<sup><a href="#ref-108">108</a></sup> and this suggests a role for the microenvironment in this subtype. In a phase I/II trial, a combination of romidepsine, lenalidomide, and carfilzomib was tried in patients with rrPTCL<sup><a href="#ref-110">110</a></sup>. In 16 evaluable patients, the CR rate was 31% (5/16) and the PR rate was 19% (3/16). Again, four out of five patients with AITL attained CR. A phase II study for untreated PTCL patients using lenalidomide plus romidepsin (NCT02232516) is ongoing.</p><p class="" id=d4678e1743>Thalidomide, a prototype drug of this class, was evaluated for combination treatment. A combination of gemcitabine, cisplatin, prednisone, and thalidomide (GDPT) was compared with CHOP for patients with newly diagnosed PTCL<sup><a href="#ref-111">111</a></sup>. In total, 103 patients were randomly allocated into two groups; 52 received GDPT and 51 received CHOP. The PFS, the primary end-point of the study, was significantly better in the GDPT arm; the two-year PFS rates were 57% versus 35% (<i>P</i> &lt;0.05). Other outcomes, including the ORR (67% versus 49%, <i>P</i> = 0.046) and the two-year OS (71% versus 50%, <i>P</i> &lt;0.05), were also favorable for the GDPT arm. Grade 3–4 myelosuppression occurred in 44% versus 41% of patients.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d4678e1762>Proteasome inhibitors</h2><p class="" id=d4678e1765>In a phase II trial, the single-agent bortezomib induced an ORR of 67% in 15 patients with rrCTCL<sup><a href="#ref-112">112</a></sup>. Because a chemosensitization effect was expected<sup><a href="#ref-113">113</a></sup>, the efficacy of bortezomib was explored in combination with CHOP in patients with newly diagnosed PTCL/ENKTL/CTCL<sup><a href="#ref-114">114</a></sup>. Of the 65 patients, 30 achieved CR (65%) and five other patients achieved PR. The ORR was 76% (35/46). When only three major subtypes of PTCLs (PTCL-NOS, AITL, and ALCL) were analyzed, the CR rate was 73% and the ORR was 87%. However, owing to frequent relapse after remission, the three-year OS and PFS rates were 47% and 35%, respectively. In another trial by the French group, the combination of bortezomib plus intensified CHOP-like regimen (ACVBP) was studied in 57 patients with newly diagnosed PTCL<sup><a href="#ref-115">115</a></sup>. The outcomes did not appear to be higher than chemotherapy alone, as the CR rate was 45%.</p><p class="" id=d4678e1784>A newer, irreversible proteasome inhibitor (carfilzomib) is currently under investigation in patients with PTCL (NCT01336920 and NCT03141203). Ixazomib, an oral proteasome inhibitor, is being assessed in a phase 2 study (NCT02158975).</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d4678e1790>Inhibitors of PI3K/mTOR pathways</h2><p class="" id=d4678e1793>PI3Ks transduce signals from various growth factors and cytokines into intracellular molecules by generating phospholipids, which then activate downstream effectors such as AKT or mTOR<sup><a href="#ref-116">116</a></sup>.</p><p class="" id=d4678e1800>Duvelisib, a dual inhibitor of PI3Kγ and δ, was studied in a phase 1 trial in patients with hematologic malignancies<sup><a href="#ref-117">117</a></sup>. Among 15 evaluable patients with rrPTCL, the ORR was 47% (7/15, two CRs and five PRs) and the median OS was 36.4 weeks. A study of duvelisib with either romidepsin or bortezomib in T-cell lymphoma is under way (NCT02783625). Another PI3K δ/γ inhibitor, RP6530, was investigated in patients with relapsed or refractory T-cell lymphoma<sup><a href="#ref-118">118</a></sup>. Among 14 evaluable patients, one CR (7%) and four PRs (29%) were noted. Copanlisib, a pan-class I inhibitor, was administered at a dose of 0.8 mg/kg on days 1, 8, and 15 of a 28-day cycle in a phase II study in which 17 patients with PTCL were included, and the ORR was 21.4%<sup><a href="#ref-119">119</a></sup>. A phase I/II study for combination of copanlisib plus gemcitabine in rrPTCL is ready to begin (NCT03052933).</p><p class="" id=d4678e1815>Given that a substantial portion of patients with PTCL show phospho-AKT overexpression, which confers a poor prognosis<sup><a href="#ref-120">120</a></sup>, AKT can be a reasonable target. In a phase II trial with MK2206, however, a frustrating result was observed; none of the three patients with PTCL responded<sup><a href="#ref-21">121</a></sup>.</p><p class="" id=d4678e1826>Activation of mTOR induces cell growth and survival in cancer, and especially in lymphoma, Myc activity is known to depend on the mTOR pathway<sup><a href="#ref-122">122</a></sup>. In a phase II study of 30 patients with untreated PTCL who received everolimus plus CHOP<sup><a href="#ref-123">123</a></sup>, CR was observed in 17 (57%) and PR was observed in 10 (33%). Despite these favorable tumor responses, frequent relapses were noted as the two-year PFS rate was 33%. Single-agent everolimus in 16 patients with relapsed or refractory T-cell lymphoma demonstrated an ORR of 44% and a median DoR of 8.5 months<sup><a href="#ref-124">124</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d4678e1845>Alternative agents</h2><div class=section><a name=d4678e1848 class=n-a></a><h3 class=section-title>Bendamustine</h3><p class="" id=d4678e1853>Bendamustine, which contains the structures of both alkylating agents and purine analogs, is one of the standard agents in indolent B-cell lymphoma. In the phase II BENTLY (Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma) trial, 60 patients with refractory or relapsed T-cell lymphoma received bendamustine at a dose of 120 mg/m<sup>2</sup> for two consecutive days every three weeks for up to six cycles<sup><a href="#ref-125">125</a></sup>. With the majority of patients having AITL and PTCL-NOS (91%), the ORR was 50% and the median DoR was 3.5 months. Major grade 3–4 toxicities were neutropenia (30%), thrombocytopenia (24%), and infection (20%). In the phase II BENCART (Bendamustine, Carboplatin and Dexamethasone for Refractory or Relapsed Peripheral T-Cell Lymphoma) trial, 30 patients with rrPTCL received a combination of bendamustine, carboplatin, and dexamethasone to proceed to ASCT<sup><a href="#ref-126">126</a></sup>. Among 28 evaluable patients, eight CRs (30%) and seven PRs (25%) were observed. The median PFS was 4.8 months.</p></div><div class=section><a name=d4678e1868 class=n-a></a><h3 class=section-title>Aurora-A kinase inhibitors</h3><p class="" id=d4678e1873>Aurora-A is a mitotic kinase overexpressed in several subtypes of PTCL<sup><a href="#ref-127">127</a></sup>. Alisertib, a small-molecule inhibitor of aurora-A kinase, has demonstrated favorable anti-tumor efficacy against rrPTCL in two phase II trials<sup><a href="#ref-128">128</a>,<a href="#ref-129">129</a></sup>. Given the promising results, a phase III LUMIERE (Alisertib or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma) trial was performed in patients with rrPTCL to compare the efficacy of alisertib versus the investigator’s choice, including pralatrexate, romidepsin, or gemcitabine<sup><a href="#ref-130">130</a></sup>. With a planned accrual of 271 patients, interim analyses were carried out after 238 patients were recruited. ORRs, the primary end-points of the study, were 33% for alisertib and 43% for the investigator’s choice<sup><a href="#ref-130">130</a></sup>. In addition, no benefit was observed across the safety profiles. With these results, the trial was prematurely terminated.</p></div><div class=section><a name=d4678e1896 class=n-a></a><h3 class=section-title>Tipifarnib</h3><p class="" id=d4678e1901>Tipifarnib is an orally administered nonpeptidomimetic farnesyl transferase inhibitor. In a phase II trial, 93 patients, including 16 patients with T-cell lymphoma, received tipifarnib 300 mg twice daily for three out of four weeks<sup><a href="#ref-131">131</a></sup>. A higher response rate was observed in the T-cell/Hodgkin’s lymphoma cohort (31%) compared with the aggressive (17%) or indolent (7%) B-cell lymphoma cohorts. Among eight patients with PTCL-NOS, three achieved CR and one achieved PR. Based on these promising results, a phase II trial was carried out solely on patients with rrPTCL, and the preliminary results were recently reported<sup><a href="#ref-132">132</a></sup>. A total of 18 patients received tipifarnib at a dose of 600 mg twice daily on days 1–7 and 15–21 in 28-day cycles, which demonstrated three PRs (17%) at the cost of grade 3–4 neutropenia (83%) and thrombocytopenia (61%).</p></div><div class=section><a name=d4678e1913 class=n-a></a><h3 class=section-title>CPI-613</h3><p class="" id=d4678e1918>CPI-613 is a novel lipoate derivative that inhibits mitochondrial metabolism in cancer cells<sup><a href="#ref-133">133</a></sup>. In a phase I trial in patients with hematologic malignancies, the maximum tolerated dose was determined to be 2,940 mg/m<sup>2</sup>, a major toxicity was renal failure<sup><a href="#ref-134">134</a></sup>. In another phase I trial in patients with relapsed or refractory T-cell lymphoma, bendamustine plus CPI-613 was administered<sup><a href="#ref-135">135</a></sup>. Out of five evaluable patients, three CRs and one PR were observed.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d4678e1940>Conclusions</h2><p class="" id=d4678e1943>Despite recent progress, there are hurdles to overcome in managing patients with PTCL, such as the poorly understood role of certain molecular features. Given the insufficient clinical outcomes out of the current standard of care, there are still unmet needs for the novel therapy.</p><p class="" id=d4678e1946>Owing to the introduction of novel therapeutic agents however, recent outcomes are worthy of attention. Tailored clinical approaches regarding what drugs to initiate, when to consolidate patients, and how to best salvage patients require further investigation, including prospective trials.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d4678e1 class=n-a></a><h2 class=main-title id=d5161>Competing interests</h2><p class=metadata-entry><a name=d4678e111 class=n-a></a><p id=d4678e112> No competing interests were disclosed.</p></p></div><div class=back-section><a name=d4678e1 class=n-a></a><h2 class=main-title id=d5163>Grant information</h2><p>The author(s) declared that no grants were involved in supporting this work.</p></div><div class=back-section><a name=d4678e1953 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d5584>References</h2><div class="section ref-list"><a name=d4678e1953 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d4678e1960 class=n-a></a>Swerdlow SH, Campo E, Pileri SA, <i> et al.</i>: The 2016 revision of the World Health Organization classification of lymphoid neoplasms. <i>Blood.</i> 2016; <b>127</b>(20): 2375–2390. <a target=xrefwindow id=d4678e1971 href="http://www.ncbi.nlm.nih.gov/pubmed/26980727">PubMed Abstract </a> | <a target=xrefwindow id=d4678e1974 href="http://dx.doi.org/10.1182/blood-2016-01-643569">Publisher Full Text </a> | <a target=xrefwindow id=d4678e1978 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4874220">Free Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d4678e1987 class=n-a></a>A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. <i>Blood.</i> 1997; <b>89</b>(11): 3909–18. <a target=xrefwindow id=d4678e1995 href="http://www.ncbi.nlm.nih.gov/pubmed/9166827">PubMed Abstract </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d4678e2004 class=n-a></a>Coiffier B, Brousse N, Peuchmaur M, <i> et al.</i>: Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives). <i>Ann Oncol.</i> 1990; <b>1</b>(1): 45–50. <a target=xrefwindow id=d4678e2015 href="http://www.ncbi.nlm.nih.gov/pubmed/1706610">PubMed Abstract </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d4678e2024 class=n-a></a>Attygalle A, Al-Jehani R, Diss TC, <i> et al.</i>: Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. <i>Blood.</i> 2002; <b>99</b>(2): 627–33. <a target=xrefwindow id=d4678e2035 href="http://www.ncbi.nlm.nih.gov/pubmed/11781247">PubMed Abstract </a> | <a target=xrefwindow id=d4678e2038 href="http://dx.doi.org/10.1182/blood.V99.2.627">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d4678e2047 class=n-a></a>de Leval L, Rickman DS, Thielen C, <i> et al.</i>: The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (T<sub>FH</sub>) cells. <i>Blood.</i> 2007; <b>109</b>(11): 4952–63. <a target=xrefwindow id=d4678e2061 href="http://www.ncbi.nlm.nih.gov/pubmed/17284527">PubMed Abstract </a> | <a target=xrefwindow id=d4678e2065 href="http://dx.doi.org/10.1182/blood-2006-10-055145">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d4678e2075 class=n-a></a>Marafioti T, Paterson JC, Ballabio E, <i> et al.</i>: The inducible T-cell co-stimulator molecule is expressed on subsets of T cells and is a new marker of lymphomas of T follicular helper cell-derivation. <i>Haematologica.</i> 2010; <b>95</b>(3): 432–9. <a target=xrefwindow id=d4678e2086 href="http://www.ncbi.nlm.nih.gov/pubmed/20207847">PubMed Abstract </a> | <a target=xrefwindow id=d4678e2089 href="http://dx.doi.org/10.3324/haematol.2009.010991">Publisher Full Text </a> | <a target=xrefwindow id=d4678e2093 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2833073">Free Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d4678e2102 class=n-a></a>Lemonnier F, Couronné L, Parrens M, <i> et al.</i>: Recurrent <i>TET2</i> mutations in peripheral T-cell lymphomas correlate with T<sub>FH</sub>-like features and adverse clinical parameters. <i>Blood.</i> 2012; <b>120</b>(7): 1466–9. <a target=xrefwindow id=d4678e2120 href="http://www.ncbi.nlm.nih.gov/pubmed/22760778">PubMed Abstract </a> | <a target=xrefwindow id=d4678e2123 href="http://dx.doi.org/10.1182/blood-2012-02-408542">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718293954"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4678e2132 class=n-a></a>Yoo HY, Sung MK, Lee SH, <i> et al.</i>: A recurrent inactivating mutation in <i>RHOA</i> GTPase in angioimmunoblastic T cell lymphoma. <i>Nat Genet.</i> 2014; <b>46</b>(4): 371–5. <a target=xrefwindow id=d4678e2146 href="http://www.ncbi.nlm.nih.gov/pubmed/24584070">PubMed Abstract </a> | <a target=xrefwindow id=d4678e2150 href="http://dx.doi.org/10.1038/ng.2916">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718293954">F1000 Recommendation</a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718235066"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4678e2163 class=n-a></a>Palomero T, Couronné L, Khiabanian H, <i> et al.</i>: Recurrent mutations in epigenetic regulators, <i>RHOA</i> and <i>FYN</i> kinase in peripheral T cell lymphomas. <i>Nat Genet.</i> 2014; <b>46</b>(2): 166–70. <a target=xrefwindow id=d4678e2181 href="http://www.ncbi.nlm.nih.gov/pubmed/24413734">PubMed Abstract </a> | <a target=xrefwindow id=d4678e2184 href="http://dx.doi.org/10.1038/ng.2873">Publisher Full Text </a> | <a target=xrefwindow id=d4678e2187 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3963408">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718235066">F1000 Recommendation</a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718235063"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4678e2200 class=n-a></a>Sakata-Yanagimoto M, Enami T, Yoshida K, <i> et al.</i>: Somatic <i>RHOA</i> mutation in angioimmunoblastic T cell lymphoma. <i>Nat Genet.</i> 2014; <b>46</b>(2): 171–5. <a target=xrefwindow id=d4678e2214 href="http://www.ncbi.nlm.nih.gov/pubmed/24413737">PubMed Abstract </a> | <a target=xrefwindow id=d4678e2218 href="http://dx.doi.org/10.1038/ng.2872">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718235063">F1000 Recommendation</a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d4678e2231 class=n-a></a>Cairns RA, Iqbal J, Lemonnier F, <i> et al.</i>: <i>IDH2</i> mutations are frequent in angioimmunoblastic T-cell lymphoma. <i>Blood.</i> 2012; <b>119</b>(8): 1901–3. <a target=xrefwindow id=d4678e2245 href="http://www.ncbi.nlm.nih.gov/pubmed/22215888">PubMed Abstract </a> | <a target=xrefwindow id=d4678e2249 href="http://dx.doi.org/10.1182/blood-2011-11-391748">Publisher Full Text </a> | <a target=xrefwindow id=d4678e2252 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3293643">Free Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d4678e2262 class=n-a></a>Iqbal J, Wright G, Wang C, <i> et al.</i>: Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. <i>Blood.</i> 2014; <b>123</b>(19): 2915–23. <a target=xrefwindow id=d4678e2273 href="http://www.ncbi.nlm.nih.gov/pubmed/24632715">PubMed Abstract </a> | <a target=xrefwindow id=d4678e2276 href="http://dx.doi.org/10.1182/blood-2013-11-536359">Publisher Full Text </a> | <a target=xrefwindow id=d4678e2280 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4014836">Free Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d4678e2289 class=n-a></a>Savage KJ, Harris NL, Vose JM, <i> et al.</i>: ALK<sup>-</sup> anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK<sup>+</sup> ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. <i>Blood.</i> 2008; <b>111</b>(12): 5496–504. <a target=xrefwindow id=d4678e2307 href="http://www.ncbi.nlm.nih.gov/pubmed/18385450">PubMed Abstract </a> | <a target=xrefwindow id=d4678e2310 href="http://dx.doi.org/10.1182/blood-2008-01-134270">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d4678e2319 class=n-a></a>Parrilla Castellar ER, Jaffe ES, Said JW, <i> et al.</i>: ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. <i>Blood.</i> 2014; <b>124</b>(9): 1473–80. <a target=xrefwindow id=d4678e2330 href="http://www.ncbi.nlm.nih.gov/pubmed/24894770">PubMed Abstract </a> | <a target=xrefwindow id=d4678e2333 href="http://dx.doi.org/10.1182/blood-2014-04-571091">Publisher Full Text </a> | <a target=xrefwindow id=d4678e2337 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4148769">Free Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d4678e2346 class=n-a></a>Keech JA Jr, Creech BJ: Anaplastic T-cell lymphoma in proximity to a saline-filled breast implant. <i>Plast Reconstr Surg.</i> 1997; <b>100</b>(2): 554–5. <a target=xrefwindow id=d4678e2354 href="http://www.ncbi.nlm.nih.gov/pubmed/9252643">PubMed Abstract </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d4678e2363 class=n-a></a>Miranda RN, Aladily TN, Prince HM, <i> et al.</i>: Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. <i>J Clin Oncol.</i> 2014; <b>32</b>(2): 114–20. <a target=xrefwindow id=d4678e2374 href="http://www.ncbi.nlm.nih.gov/pubmed/24323027">PubMed Abstract </a> | <a target=xrefwindow id=d4678e2377 href="http://dx.doi.org/10.1200/JCO.2013.52.7911">Publisher Full Text </a> | <a target=xrefwindow id=d4678e2381 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4062709">Free Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725957551"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4678e2390 class=n-a></a>Laurent C, Delas A, Gaulard P, <i> et al.</i>: Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes. <i>Ann Oncol.</i> 2016; <b>27</b>(2): 306–14. <a target=xrefwindow id=d4678e2401 href="http://www.ncbi.nlm.nih.gov/pubmed/26598546">PubMed Abstract </a> | <a target=xrefwindow id=d4678e2404 href="http://dx.doi.org/10.1093/annonc/mdv575">Publisher Full Text </a> | <a target=xrefwindow id=d4678e2408 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4722894">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725957551">F1000 Recommendation</a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d4678e2422 class=n-a></a>Tan SY, Ooi AS, Ang MK, <i> et al.</i>: Nuclear expression of MATK is a novel marker of type II enteropathy-associated T-cell lymphoma. <i>Leukemia.</i> 2011; <b>25</b>(3): 555–7. <a target=xrefwindow id=d4678e2433 href="http://www.ncbi.nlm.nih.gov/pubmed/21233830">PubMed Abstract </a> | <a target=xrefwindow id=d4678e2436 href="http://dx.doi.org/10.1038/leu.2010.295">Publisher Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d4678e2445 class=n-a></a>Tan SY, Chuang SS, Tang T, <i> et al.</i>: Type II EATL (epitheliotropic intestinal T-cell lymphoma): a neoplasm of intra-epithelial T-cells with predominant CD8αα phenotype. <i>Leukemia.</i> 2013; <b>27</b>(8): 1688–96. <a target=xrefwindow id=d4678e2456 href="http://www.ncbi.nlm.nih.gov/pubmed/23399895">PubMed Abstract </a> | <a target=xrefwindow id=d4678e2459 href="http://dx.doi.org/10.1038/leu.2013.41">Publisher Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726717372"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4678e2468 class=n-a></a>Roberti A, Dobay MP, Bisig B, <i> et al.</i>: Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent <i>SETD2</i> alterations. <i>Nat Commun.</i> 2016; <b>7</b>: 12602. <a target=xrefwindow id=d4678e2482 href="http://www.ncbi.nlm.nih.gov/pubmed/27600764">PubMed Abstract </a> | <a target=xrefwindow id=d4678e2486 href="http://dx.doi.org/10.1038/ncomms12602">Publisher Full Text </a> | <a target=xrefwindow id=d4678e2489 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5023950">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726717372">F1000 Recommendation</a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d4678e2502 class=n-a></a>Perry AM, Warnke RA, Hu Q, <i> et al.</i>: Indolent T-cell lymphoproliferative disease of the gastrointestinal tract. <i>Blood.</i> 2013; <b>122</b>(22): 3599–606. <a target=xrefwindow id=d4678e2513 href="http://www.ncbi.nlm.nih.gov/pubmed/24009234">PubMed Abstract </a> | <a target=xrefwindow id=d4678e2516 href="http://dx.doi.org/10.1182/blood-2013-07-512830">Publisher Full Text </a> | <a target=xrefwindow id=d4678e2520 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3837508">Free Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d4678e2529 class=n-a></a>Margolskee E, Jobanputra V, Lewis SK, <i> et al.</i>: Indolent small intestinal CD4+ T-cell lymphoma is a distinct entity with unique biologic and clinical features. <i>PLoS One.</i> 2013; <b>8</b>(7): e68343. <a target=xrefwindow id=d4678e2540 href="http://www.ncbi.nlm.nih.gov/pubmed/23861889">PubMed Abstract </a> | <a target=xrefwindow id=d4678e2543 href="http://dx.doi.org/10.1371/journal.pone.0068343">Publisher Full Text </a> | <a target=xrefwindow id=d4678e2547 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3701677">Free Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726707279"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4678e2556 class=n-a></a>Horwitz SM, Zelenetz AD, Gordon LI, <i> et al.</i>: NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. <i>J Natl Compr Canc Netw.</i> 2016; <b>14</b>(9): 1067–79. <a target=xrefwindow id=d4678e2567 href="http://www.ncbi.nlm.nih.gov/pubmed/27587620">PubMed Abstract </a> | <a target=xrefwindow id=d4678e2570 href="http://dx.doi.org/10.6004/jnccn.2016.0117">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726707279">F1000 Recommendation</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d4678e2584 class=n-a></a>d'Amore F, Gaulard P, Trümper L, <i> et al.</i>: Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol.</i> 2015; <b>26 Suppl 5</b>: v108–15. <a target=xrefwindow id=d4678e2595 href="http://www.ncbi.nlm.nih.gov/pubmed/26314772">PubMed Abstract </a> | <a target=xrefwindow id=d4678e2598 href="http://dx.doi.org/10.1093/annonc/mdv201">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d4678e2607 class=n-a></a>Savage KJ, Chhanabhai M, Gascoyne RD, <i> et al.</i>: Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. <i>Ann Oncol.</i> 2004; <b>15</b>(10): 1467–75. <a target=xrefwindow id=d4678e2618 href="http://www.ncbi.nlm.nih.gov/pubmed/15367405">PubMed Abstract </a> | <a target=xrefwindow id=d4678e2621 href="http://dx.doi.org/10.1093/annonc/mdh392">Publisher Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1123370"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4678e2630 class=n-a></a>Vose J, Armitage J, Weisenburger D, <i> et al.</i>: International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. <i>J Clin Oncol.</i> 2008; <b>26</b>(25): 4124–30. <a target=xrefwindow id=d4678e2641 href="http://www.ncbi.nlm.nih.gov/pubmed/18626005">PubMed Abstract </a> | <a target=xrefwindow id=d4678e2644 href="http://dx.doi.org/10.1200/JCO.2008.16.4558">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1123370">F1000 Recommendation</a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d4678e2657 class=n-a></a>Abouyabis AN, Shenoy PJ, Sinha R, <i> et al.</i>: A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma. <i>ISRN Hematol.</i> 2011; <b>2011</b>: 623924. <a target=xrefwindow id=d4678e2668 href="http://www.ncbi.nlm.nih.gov/pubmed/22084700">PubMed Abstract </a> | <a target=xrefwindow id=d4678e2671 href="http://dx.doi.org/10.5402/2011/623924">Publisher Full Text </a> | <a target=xrefwindow id=d4678e2675 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3197255">Free Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d4678e2684 class=n-a></a>Escalón MP, Liu NS, Yang Y, <i> et al.</i>: Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. <i>Cancer.</i> 2005; <b>103</b>(10): 2091–8. <a target=xrefwindow id=d4678e2695 href="http://www.ncbi.nlm.nih.gov/pubmed/15816054">PubMed Abstract </a> | <a target=xrefwindow id=d4678e2698 href="http://dx.doi.org/10.1002/cncr.20999">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d4678e2707 class=n-a></a>Peng YL, Huang HQ, Lin XB, <i> et al.</i>: [Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen]. <i>Ai Zheng.</i> 2004; <b>23</b>(8): 943–6. <a target=xrefwindow id=d4678e2718 href="http://www.ncbi.nlm.nih.gov/pubmed/15301720">PubMed Abstract </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d4678e2728 class=n-a></a>Simon A, Peoch M, Casassus P, <i> et al.</i>: Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. <i>Br J Haematol.</i> 2010; <b>151</b>(2): 159–66. <a target=xrefwindow id=d4678e2739 href="http://www.ncbi.nlm.nih.gov/pubmed/20738307">PubMed Abstract </a> | <a target=xrefwindow id=d4678e2742 href="http://dx.doi.org/10.1111/j.1365-2141.2010.08329.x">Publisher Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d4678e2751 class=n-a></a>Tilly H, Lepage E, Coiffier B, <i> et al.</i>: Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. <i>Blood.</i> 2003; <b>102</b>(13): 4284–9. <a target=xrefwindow id=d4678e2762 href="http://www.ncbi.nlm.nih.gov/pubmed/12920037">PubMed Abstract </a> | <a target=xrefwindow id=d4678e2765 href="http://dx.doi.org/10.1182/blood-2003-02-0542">Publisher Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d4678e2774 class=n-a></a>Niitsu N, Hayama M, Yoshino T, <i> et al.</i>: Multicentre phase II study of the CyclOBEAP regimen for patients with peripheral T-cell lymphoma with analysis of biomarkers. <i>Br J Haematol.</i> 2011; <b>153</b>(5): 582–8. <a target=xrefwindow id=d4678e2785 href="http://www.ncbi.nlm.nih.gov/pubmed/21492124">PubMed Abstract </a> | <a target=xrefwindow id=d4678e2788 href="http://dx.doi.org/10.1111/j.1365-2141.2011.08634.x">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d4678e2797 class=n-a></a>Pfreundschuh M, Trümper L, Kloess M, <i> et al.</i>: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. <i>Blood.</i> 2004; <b>104</b>(3): 626–33. <a target=xrefwindow id=d4678e2808 href="http://www.ncbi.nlm.nih.gov/pubmed/14982884">PubMed Abstract </a> | <a target=xrefwindow id=d4678e2811 href="http://dx.doi.org/10.1182/blood-2003-06-2094">Publisher Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d4678e2820 class=n-a></a>Pfreundschuh M, Trümper L, Kloess M, <i> et al.</i>: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. <i>Blood.</i> 2004; <b>104</b>(3): 634–41. <a target=xrefwindow id=d4678e2831 href="http://www.ncbi.nlm.nih.gov/pubmed/15016643">PubMed Abstract </a> | <a target=xrefwindow id=d4678e2834 href="http://dx.doi.org/10.1182/blood-2003-06-2095">Publisher Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d4678e2843 class=n-a></a>Mahadevan D, Unger JM, Spier CM, <i> et al.</i>: Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. <i>Cancer.</i> 2013; <b>119</b>(2): 371–9. <a target=xrefwindow id=d4678e2854 href="http://www.ncbi.nlm.nih.gov/pubmed/22833464">PubMed Abstract </a> | <a target=xrefwindow id=d4678e2857 href="http://dx.doi.org/10.1002/cncr.27733">Publisher Full Text </a> | <a target=xrefwindow id=d4678e2861 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3485430">Free Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d4678e2871 class=n-a></a>Kim JG, Sohn SK, Chae YS, <i> et al.</i>: CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas. <i>Cancer Chemother Pharmacol.</i> 2006; <b>58</b>(1): 35–9. <a target=xrefwindow id=d4678e2882 href="http://www.ncbi.nlm.nih.gov/pubmed/16308699">PubMed Abstract </a> | <a target=xrefwindow id=d4678e2885 href="http://dx.doi.org/10.1007/s00280-005-0136-y">Publisher Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d4678e2894 class=n-a></a>Gleeson M, Peckitt C, To YM, <i> et al.</i>: CHOP VERSUS GEM-P IN THE FIRST-LINE TREATMENT OF T-CELL LYMPHOMA (PTCL): INITIAL RESULTS OF THE UK NRCI PHASE II RANDOMISED CHEMO-T TRIAL. <i>Hematol Oncol.</i> 2017; <b>35</b>: 75–6. <a target=xrefwindow id=d4678e2905 href="http://dx.doi.org/10.1002/hon.2437_63">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d4678e2914 class=n-a></a>Reimer P, Rüdiger T, Geissinger E, <i> et al.</i>: Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. <i>J Clin Oncol.</i> 2009; <b>27</b>(1): 106–13. <a target=xrefwindow id=d4678e2925 href="http://www.ncbi.nlm.nih.gov/pubmed/19029417">PubMed Abstract </a> | <a target=xrefwindow id=d4678e2928 href="http://dx.doi.org/10.1200/JCO.2008.17.4870">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717954687"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4678e2937 class=n-a></a>d'Amore F, Relander T, Lauritzsen GF, <i> et al.</i>: Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. <i>J Clin Oncol.</i> 2012; <b>30</b>(25): 3093–9. <a target=xrefwindow id=d4678e2948 href="http://www.ncbi.nlm.nih.gov/pubmed/22851556">PubMed Abstract </a> | <a target=xrefwindow id=d4678e2951 href="http://dx.doi.org/10.1200/JCO.2011.40.2719">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717954687">F1000 Recommendation</a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d4678e2964 class=n-a></a>d'Amore F, Relander T, Lauritzsen G, <i> et al.</i>: TEN YEARS MEDIAN FOLLOW-UP OF THE NORDIC NLG-T-01 TRIAL ON CHOEP AND UPFRONT AUTOLOGOUS TRANSPLANTATION IN PERIPHERAL T-CELL LYMPHOMAS. <i>Hematol Oncol.</i> 2015; <b>33</b>: 139–140, [Internet]. <a target=xrefwindow id=d4678e2975 href="https://insights.ovid.com/hematological-oncology/honc/2015/06/001/ten-years-median-follow-nordic-nlg-01-trial-choep/93/01445428">Reference Source</a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d4678e2984 class=n-a></a>Norbert Schmitz MN, Altmann B, Ziepert M, <i> et al.</i>: Allogeneic or autologous transplantation as first-line therapy for younger patients with peripheral T-cell lymphoma: Results of the interim analysis of the AATT trial. ASCO annual meeting. <i>J Clin Oncol.</i> 2015; <b>33</b>(15_suppl): 8507–8507. <a target=xrefwindow id=d4678e2995 href="http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.8507">Reference Source</a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725339459"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4678e3005 class=n-a></a>Beitinjaneh A, Saliba RM, Medeiros LJ, <i> et al.</i>: Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease. <i>Biol Blood Marrow Transplant.</i> 2015; <b>21</b>(5): 855–9. <a target=xrefwindow id=d4678e3016 href="http://www.ncbi.nlm.nih.gov/pubmed/25652691">PubMed Abstract </a> | <a target=xrefwindow id=d4678e3019 href="http://dx.doi.org/10.1016/j.bbmt.2015.01.013">Publisher Full Text </a> | <a target=xrefwindow id=d4678e3023 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4408269">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725339459">F1000 Recommendation</a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718002433"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4678e3036 class=n-a></a>Mak V, Hamm J, Chhanabhai M, <i> et al.</i>: Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. <i>J Clin Oncol.</i> 2013; <b>31</b>(16): 1970–6. <a target=xrefwindow id=d4678e3047 href="http://www.ncbi.nlm.nih.gov/pubmed/23610113">PubMed Abstract </a> | <a target=xrefwindow id=d4678e3050 href="http://dx.doi.org/10.1200/JCO.2012.44.7524">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718002433">F1000 Recommendation</a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d4678e3063 class=n-a></a>Enblad G, Hagberg H, Erlanson M, <i> et al.</i>: A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. <i>Blood.</i> 2004; <b>103</b>(8): 2920–4. <a target=xrefwindow id=d4678e3074 href="http://www.ncbi.nlm.nih.gov/pubmed/15070664">PubMed Abstract </a> | <a target=xrefwindow id=d4678e3077 href="http://dx.doi.org/10.1182/blood-2003-10-3389">Publisher Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d4678e3086 class=n-a></a>Kim SJ, Kim K, Kim BS, <i> et al.</i>: Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study. <i>Ann Oncol.</i> 2009; <b>20</b>(2): 390–2. <a target=xrefwindow id=d4678e3097 href="http://www.ncbi.nlm.nih.gov/pubmed/19211502">PubMed Abstract </a> | <a target=xrefwindow id=d4678e3100 href="http://dx.doi.org/10.1093/annonc/mdn726">Publisher Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d4678e3109 class=n-a></a>Weidmann E, Hess G, Chow KU, <i> et al.</i>: A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas. <i>Leuk Lymphoma.</i> 2010; <b>51</b>(3): 447–55. <a target=xrefwindow id=d4678e3120 href="http://www.ncbi.nlm.nih.gov/pubmed/20141439">PubMed Abstract </a> | <a target=xrefwindow id=d4678e3123 href="http://dx.doi.org/10.3109/10428190903580402">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d4678e3132 class=n-a></a>Ravandi F, Aribi A, O'Brien S, <i> et al.</i>: Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. <i>J Clin Oncol.</i> 2009; <b>27</b>(32): 5425–30. <a target=xrefwindow id=d4678e3143 href="http://www.ncbi.nlm.nih.gov/pubmed/19805674">PubMed Abstract </a> | <a target=xrefwindow id=d4678e3146 href="http://dx.doi.org/10.1200/JCO.2009.22.6688">Publisher Full Text </a> | <a target=xrefwindow id=d4678e3150 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4881363">Free Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d4678e3160 class=n-a></a>Kim JG, Sohn SK, Chae YS, <i> et al.</i>: Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. <i>Cancer Chemother Pharmacol.</i> 2007; <b>60</b>(1): 129–34. <a target=xrefwindow id=d4678e3171 href="http://www.ncbi.nlm.nih.gov/pubmed/17406867">PubMed Abstract </a> | <a target=xrefwindow id=d4678e3174 href="http://dx.doi.org/10.1007/s00280-007-0469-9">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d4678e3183 class=n-a></a>Kluin-Nelemans HC, van Marwijk Kooy M, Lugtenburg PJ, <i> et al.</i>: Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. <i>Ann Oncol.</i> 2011; <b>22</b>(7): 1595–600. <a target=xrefwindow id=d4678e3194 href="http://www.ncbi.nlm.nih.gov/pubmed/21212158">PubMed Abstract </a> | <a target=xrefwindow id=d4678e3197 href="http://dx.doi.org/10.1093/annonc/mdq635">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d4678e3206 class=n-a></a>Gallamini A, Zaja F, Patti C, <i> et al.</i>: Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. <i>Blood.</i> 2007; <b>110</b>(7): 2316–23. <a target=xrefwindow id=d4678e3217 href="http://www.ncbi.nlm.nih.gov/pubmed/17581918">PubMed Abstract </a> | <a target=xrefwindow id=d4678e3220 href="http://dx.doi.org/10.1182/blood-2007-02-074641">Publisher Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d4678e3229 class=n-a></a>Binder C, Ziepert M, Pfreundschuh M, <i> et al.</i>: CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T cell lymphomas: final analysis of a prospective phase II trial. <i>Ann Hematol.</i> 2013; <b>92</b>(11): 1521–8. <a target=xrefwindow id=d4678e3240 href="http://www.ncbi.nlm.nih.gov/pubmed/23978945">PubMed Abstract </a> | <a target=xrefwindow id=d4678e3243 href="http://dx.doi.org/10.1007/s00277-013-1880-4">Publisher Full Text </a> | <a target=xrefwindow id=d4678e3247 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3790248">Free Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d4678e3256 class=n-a></a>Pro B, Advani R, Brice P, <i> et al.</i>: Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. <i>J Clin Oncol.</i> 2012; <b>30</b>(18): 2190–6. <a target=xrefwindow id=d4678e3267 href="http://www.ncbi.nlm.nih.gov/pubmed/22614995">PubMed Abstract </a> | <a target=xrefwindow id=d4678e3270 href="http://dx.doi.org/10.1200/JCO.2011.38.0402">Publisher Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d4678e3279 class=n-a></a>Pro B, Advani R, Brice P, <i> et al.</i>: Four-Year Survival Data from an Ongoing Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. American Society of Hematology 56th Annual Meeting (2014), <i>Blood.</i> 2014; <b>124</b>(21): 3095. <a target=xrefwindow id=d4678e3290 href="http://www.bloodjournal.org/content/124/21/3095?sso-checked=true">Reference Source</a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d4678e3300 class=n-a></a>Pro B, Advani RH, Brice P, <i> et al.</i>: Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. American Society of Hematology 58th Annual Meeting (2016), <i>Blood.</i> 2016; <b>128</b>(22): 4144. <a target=xrefwindow id=d4678e3311 href="http://www.bloodjournal.org/content/128/22/4144?sso-checked=true&amp;utm_source=TrendMD&amp;utm_medium=cpc&amp;utm_campaign=Blood_TrendMD_0">Reference Source</a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d4678e3320 class=n-a></a>Weisenburger DD, Savage KJ, Harris NL, <i> et al.</i>: Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. <i>Blood.</i> 2011; <b>117</b>(12): 3402–8. <a target=xrefwindow id=d4678e3331 href="http://www.ncbi.nlm.nih.gov/pubmed/21270441">PubMed Abstract </a> | <a target=xrefwindow id=d4678e3334 href="http://dx.doi.org/10.1182/blood-2010-09-310342">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d4678e3343 class=n-a></a>Murray A, Cuevas EC, Jones DB, <i> et al.</i>: Study of the immunohistochemistry and T cell clonality of enteropathy-associated T cell lymphoma. <i>Am J Pathol.</i> 1995; <b>146</b>(2): 509–19. <a target=xrefwindow id=d4678e3354 href="http://www.ncbi.nlm.nih.gov/pubmed/7856760">PubMed Abstract </a> | <a target=xrefwindow id=d4678e3357 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1869840">Free Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d4678e3366 class=n-a></a>Schwartz EJ, Molina-Kirsch H, Zhao S, <i> et al.</i>: Immunohistochemical characterization of nasal-type extranodal NK/T-cell lymphoma using a tissue microarray: an analysis of 84 cases. <i>Am J Clin Pathol.</i> 2008; <b>130</b>(3): 343–51. <a target=xrefwindow id=d4678e3377 href="http://www.ncbi.nlm.nih.gov/pubmed/18701406">PubMed Abstract </a> | <a target=xrefwindow id=d4678e3380 href="http://dx.doi.org/10.1309/V561QTM6854W4WAV">Publisher Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d4678e3389 class=n-a></a>Horwitz SM, Advani RH, Bartlett NL, <i> et al.</i>: Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. <i>Blood.</i> 2014; <b>123</b>(20): 3095–100. <a target=xrefwindow id=d4678e3400 href="http://www.ncbi.nlm.nih.gov/pubmed/24652992">PubMed Abstract </a> | <a target=xrefwindow id=d4678e3403 href="http://dx.doi.org/10.1182/blood-2013-12-542142">Publisher Full Text </a> | <a target=xrefwindow id=d4678e3407 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4425442">Free Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d4678e3416 class=n-a></a>Fanale MA, Horwitz SM, Forero-Torres A, <i> et al.</i>: Brentuximab vedotin in the front-line treatment of patients with CD30<sup>+</sup> peripheral T-cell lymphomas: results of a phase I study. <i>J Clin Oncol.</i> 2014; <b>32</b>(28): 3137–43. <a target=xrefwindow id=d4678e3430 href="http://www.ncbi.nlm.nih.gov/pubmed/25135998">PubMed Abstract </a> | <a target=xrefwindow id=d4678e3434 href="http://dx.doi.org/10.1200/JCO.2013.54.2456">Publisher Full Text </a> | <a target=xrefwindow id=d4678e3437 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4171358">Free Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d4678e3447 class=n-a></a>Fanale MA, Horwitz SM, Forero-Torres A, <i> et al.</i>: Four-Year Survival and Durability Results of Brentuximab Vedotin in Combination with CHP in the Frontline Treatment of Patients with CD30-Expressing Peripheral T-Cell Lymphomas. American Society of Hematology 58th Annual Meeting (2016), <i>Blood.</i> 2016; <b>128</b>(22): 2993. <a target=xrefwindow id=d4678e3458 href="http://www.bloodjournal.org/content/128/22/2993">Reference Source</a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d4678e3467 class=n-a></a>Ishida T, Utsunomiya A, Iida S, <i> et al.</i>: Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. <i>Clin Cancer Res.</i> 2003; <b>9</b>(10 Pt 1): 3625–34. <a target=xrefwindow id=d4678e3478 href="http://www.ncbi.nlm.nih.gov/pubmed/14506150">PubMed Abstract </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d4678e3487 class=n-a></a>Ishida T, Inagaki H, Utsunomiya A, <i> et al.</i>: CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. <i>Clin Cancer Res.</i> 2004; <b>10</b>(16): 5494–500. <a target=xrefwindow id=d4678e3498 href="http://www.ncbi.nlm.nih.gov/pubmed/15328188">PubMed Abstract </a> | <a target=xrefwindow id=d4678e3501 href="http://dx.doi.org/10.1158/1078-0432.CCR-04-0371">Publisher Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d4678e3510 class=n-a></a>Jones D, O'Hara C, Kraus MD, <i> et al.</i>: Expression pattern of T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma. <i>Blood.</i> 2000; <b>96</b>(2): 685–90. <a target=xrefwindow id=d4678e3521 href="http://www.ncbi.nlm.nih.gov/pubmed/10887135">PubMed Abstract </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d4678e3530 class=n-a></a>Ogura M, Ishida T, Hatake K, <i> et al.</i>: Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. <i>J Clin Oncol.</i> 2014; <b>32</b>(11): 1157–63. <a target=xrefwindow id=d4678e3541 href="http://www.ncbi.nlm.nih.gov/pubmed/24616310">PubMed Abstract </a> | <a target=xrefwindow id=d4678e3544 href="http://dx.doi.org/10.1200/JCO.2013.52.0924">Publisher Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726034691"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4678e3553 class=n-a></a>Dupuis J, Morschhauser F, Ghesquières H, <i> et al.</i>: Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study. <i>Lancet Haematol.</i> 2015; <b>2</b>(4): e160–5. <a target=xrefwindow id=d4678e3564 href="http://www.ncbi.nlm.nih.gov/pubmed/26687958">PubMed Abstract </a> | <a target=xrefwindow id=d4678e3567 href="http://dx.doi.org/10.1016/S2352-3026(15)00023-X">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726034691">F1000 Recommendation</a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d4678e3581 class=n-a></a>Yamamoto R, Nishikori M, Kitawaki T, <i> et al.</i>: PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. <i>Blood.</i> 2008; <b>111</b>(6): 3220–4. <a target=xrefwindow id=d4678e3592 href="http://www.ncbi.nlm.nih.gov/pubmed/18203952">PubMed Abstract </a> | <a target=xrefwindow id=d4678e3595 href="http://dx.doi.org/10.1182/blood-2007-05-085159">Publisher Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d4678e3604 class=n-a></a>Mittal S, Marshall NA, Duncan L, <i> et al.</i>: Local and systemic induction of CD4<sup>+</sup>CD25<sup>+</sup> regulatory T-cell population by non-Hodgkin lymphoma. <i>Blood.</i> 2008; <b>111</b>(11): 5359–70. <a target=xrefwindow id=d4678e3622 href="http://www.ncbi.nlm.nih.gov/pubmed/18305220">PubMed Abstract </a> | <a target=xrefwindow id=d4678e3625 href="http://dx.doi.org/10.1182/blood-2007-08-105395">Publisher Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d4678e3634 class=n-a></a>Dorfman DM, Brown JA, Shahsafaei A, <i> et al.</i>: Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. <i>Am J Surg Pathol.</i> 2006; <b>30</b>(7): 802–10. <a target=xrefwindow id=d4678e3645 href="http://www.ncbi.nlm.nih.gov/pubmed/16819321">PubMed Abstract </a> | <a target=xrefwindow id=d4678e3648 href="http://dx.doi.org/10.1097/01.pas.0000209855.28282.ce">Publisher Full Text </a> | <a target=xrefwindow id=d4678e3652 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3137919">Free Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d4678e3661 class=n-a></a>Chen BJ, Chapuy B, Ouyang J, <i> et al.</i>: PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. <i>Clin Cancer Res.</i> 2013; <b>19</b>(13): 3462–73. <a target=xrefwindow id=d4678e3672 href="http://www.ncbi.nlm.nih.gov/pubmed/23674495">PubMed Abstract </a> | <a target=xrefwindow id=d4678e3675 href="http://dx.doi.org/10.1158/1078-0432.CCR-13-0855">Publisher Full Text </a> | <a target=xrefwindow id=d4678e3679 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4102335">Free Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726406639"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4678e3688 class=n-a></a>Lesokhin AM, Ansell SM, Armand P, <i> et al.</i>: Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. <i>J Clin Oncol.</i> 2016; <b>34</b>(23): 2698–704. <a target=xrefwindow id=d4678e3699 href="http://www.ncbi.nlm.nih.gov/pubmed/27269947">PubMed Abstract </a> | <a target=xrefwindow id=d4678e3702 href="http://dx.doi.org/10.1200/JCO.2015.65.9789">Publisher Full Text </a> | <a target=xrefwindow id=d4678e3706 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5019749">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726406639">F1000 Recommendation</a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d4678e3719 class=n-a></a>Chan TS, Khong PL, Kwong YL: Pembrolizumab for relapsed anaplastic large cell lymphoma after allogeneic haematopoietic stem cell transplantation: efficacy and safety. <i>Ann Hematol.</i> 2016; <b>95</b>(11): 1913–5. <a target=xrefwindow id=d4678e3727 href="http://www.ncbi.nlm.nih.gov/pubmed/27473193">PubMed Abstract </a> | <a target=xrefwindow id=d4678e3730 href="http://dx.doi.org/10.1007/s00277-016-2764-1">Publisher Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d4678e3740 class=n-a></a>Kwong YL, Chan TSY, Tan D, <i> et al.</i>: PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. <i>Blood.</i> 2017; <b>129</b>(17): 2437–42. <a target=xrefwindow id=d4678e3751 href="http://www.ncbi.nlm.nih.gov/pubmed/28188133">PubMed Abstract </a> | <a target=xrefwindow id=d4678e3754 href="http://dx.doi.org/10.1182/blood-2016-12-756841">Publisher Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d4678e3763 class=n-a></a>Ansell S, Gutierrez ME, Shipp MA, <i> et al.</i>: A Phase 1 Study of Nivolumab in Combination with Ipilimumab for Relapsed or Refractory Hematologic Malignancies (CheckMate 039). 58th Annual Meeting of American Society of Hematology, 2016. <a target=xrefwindow id=d4678e3768 href="http://www.myelomabeacon.com/resources/mtgs/ash2016/abs/183/">Reference Source</a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d4678e3777 class=n-a></a>Marchi E, Mangone M, Zullo K, <i> et al.</i>: Pralatrexate pharmacology and clinical development. <i>Clin Cancer Res.</i> 2013; <b>19</b>(24): 6657–61. <a target=xrefwindow id=d4678e3788 href="http://www.ncbi.nlm.nih.gov/pubmed/23965902">PubMed Abstract </a> | <a target=xrefwindow id=d4678e3791 href="http://dx.doi.org/10.1158/1078-0432.CCR-12-2251">Publisher Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1164893"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4678e3800 class=n-a></a>O'Connor OA, Horwitz S, Hamlin P, <i> et al.</i>: Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. <i>J Clin Oncol.</i> 2009; <b>27</b>(26): 4357–64. <a target=xrefwindow id=d4678e3811 href="http://www.ncbi.nlm.nih.gov/pubmed/19652067">PubMed Abstract </a> | <a target=xrefwindow id=d4678e3814 href="http://dx.doi.org/10.1200/JCO.2008.20.8470">Publisher Full Text </a> | <a target=xrefwindow id=d4678e3818 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3651599">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1164893">F1000 Recommendation</a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/9402956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4678e3831 class=n-a></a>O'Connor OA, Pro B, Pinter-Brown L, <i> et al.</i>: Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. <i>J Clin Oncol.</i> 2011; <b>29</b>(9): 1182–9. <a target=xrefwindow id=d4678e3842 href="http://www.ncbi.nlm.nih.gov/pubmed/21245435">PubMed Abstract </a> | <a target=xrefwindow id=d4678e3845 href="http://dx.doi.org/10.1200/JCO.2010.29.9024">Publisher Full Text </a> | <a target=xrefwindow id=d4678e3849 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3083873">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/9402956">F1000 Recommendation</a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727876327"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4678e3862 class=n-a></a>Maruyama D, Nagai H, Maeda Y, <i> et al.</i>: Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma. <i>Cancer Sci.</i> 2017; <b>108</b>(10): 2061–8. <a target=xrefwindow id=d4678e3873 href="http://www.ncbi.nlm.nih.gov/pubmed/28771889">PubMed Abstract </a> | <a target=xrefwindow id=d4678e3876 href="http://dx.doi.org/10.1111/cas.13340">Publisher Full Text </a> | <a target=xrefwindow id=d4678e3880 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5623731">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727876327">F1000 Recommendation</a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d4678e3894 class=n-a></a>Toner LE, Vrhovac R, Smith EA, <i> et al.</i>: The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma. <i>Clin Cancer Res.</i> 2006; <b>12</b>(3 Pt 1): 924–32. <a target=xrefwindow id=d4678e3905 href="http://www.ncbi.nlm.nih.gov/pubmed/16467107">PubMed Abstract </a> | <a target=xrefwindow id=d4678e3908 href="http://dx.doi.org/10.1158/1078-0432.CCR-05-0331">Publisher Full Text </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d4678e3917 class=n-a></a>Marchi E, Paoluzzi L, Scotto L, <i> et al.</i>: Pralatrexate is synergistic with the proteasome inhibitor bortezomib in <i>in vitro</i> and <i>in vivo</i> models of T-cell lymphoid malignancies. <i>Clin Cancer Res.</i> 2010; <b>16</b>(14): 3648–58. <a target=xrefwindow id=d4678e3935 href="http://www.ncbi.nlm.nih.gov/pubmed/20501616">PubMed Abstract </a> | <a target=xrefwindow id=d4678e3938 href="http://dx.doi.org/10.1158/1078-0432.CCR-10-0671">Publisher Full Text </a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725980628"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4678e3947 class=n-a></a>Advani RH, Ansell SM, Lechowicz MJ, <i> et al.</i>: A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial. <i>Br J Haematol.</i> 2016; <b>172</b>(4): 535–44. <a target=xrefwindow id=d4678e3958 href="http://www.ncbi.nlm.nih.gov/pubmed/26627450">PubMed Abstract </a> | <a target=xrefwindow id=d4678e3961 href="http://dx.doi.org/10.1111/bjh.13855">Publisher Full Text </a> | <a target=xrefwindow id=d4678e3965 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5642048">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725980628">F1000 Recommendation</a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a name=d4678e3978 class=n-a></a>Horwitz SM, Vose JM, Advani R, <i> et al.</i>: Pralatrexate and Gemcitabine in Patients with Relapsed or Refractory Lymphoproliferative Malignancies: Phase 1 Results. (#1674). Annual Meeting of American Society of Hematology. <i>Blood.</i> 2009; <b>114</b>(22): 1674. <a target=xrefwindow id=d4678e3989 href="http://www.bloodjournal.org/content/114/22/1674?sso-checked=true">Reference Source</a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726571065"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4678e3998 class=n-a></a>Lee SS, Jung SH, Ahn JS, <i> et al.</i>: Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients. <i>J Korean Med Sci.</i> 2016; <b>31</b>(7): 1160–3. <a target=xrefwindow id=d4678e4009 href="http://www.ncbi.nlm.nih.gov/pubmed/27366017">PubMed Abstract </a> | <a target=xrefwindow id=d4678e4012 href="http://dx.doi.org/10.3346/jkms.2016.31.7.1160">Publisher Full Text </a> | <a target=xrefwindow id=d4678e4016 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4901011">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726571065">F1000 Recommendation</a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d4678e4029 class=n-a></a>Marks PA, Richon VM, Rifkind RA: Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. <i>J Natl Cancer Inst.</i> 2000; <b>92</b>(15): 1210–6. <a target=xrefwindow id=d4678e4037 href="http://www.ncbi.nlm.nih.gov/pubmed/10922406">PubMed Abstract </a> | <a target=xrefwindow id=d4678e4040 href="http://dx.doi.org/10.1093/jnci/92.15.1210">Publisher Full Text </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a name=d4678e4050 class=n-a></a>Bolden JE, Peart MJ, Johnstone RW: Anticancer activities of histone deacetylase inhibitors. <i>Nat Rev Drug Discov.</i> 2006; <b>5</b>(9): 769–84. <a target=xrefwindow id=d4678e4058 href="http://www.ncbi.nlm.nih.gov/pubmed/16955068">PubMed Abstract </a> | <a target=xrefwindow id=d4678e4061 href="http://dx.doi.org/10.1038/nrd2133">Publisher Full Text </a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d4678e4070 class=n-a></a>Marquard L, Poulsen CB, Gjerdrum LM, <i> et al.</i>: Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas. <i>Histopathology.</i> 2009; <b>54</b>(6): 688–98. <a target=xrefwindow id=d4678e4081 href="http://www.ncbi.nlm.nih.gov/pubmed/19438744">PubMed Abstract </a> | <a target=xrefwindow id=d4678e4084 href="http://dx.doi.org/10.1111/j.1365-2559.2009.03290.x">Publisher Full Text </a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a name=d4678e4093 class=n-a></a>Gloghini A, Buglio D, Khaskhely NM, <i> et al.</i>: Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors. <i>Br J Haematol.</i> 2009; <b>147</b>(4): 515–25. <a target=xrefwindow id=d4678e4104 href="http://www.ncbi.nlm.nih.gov/pubmed/19775297">PubMed Abstract </a> | <a target=xrefwindow id=d4678e4107 href="http://dx.doi.org/10.1111/j.1365-2141.2009.07887.x">Publisher Full Text </a> | <a target=xrefwindow id=d4678e4111 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3181219">Free Full Text </a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a name=d4678e4120 class=n-a></a>Piekarz RL, Robey R, Sandor V, <i> et al.</i>: Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. <i>Blood.</i> 2001; <b>98</b>(9): 2865–8. <a target=xrefwindow id=d4678e4131 href="http://www.ncbi.nlm.nih.gov/pubmed/11675364">PubMed Abstract </a> | <a target=xrefwindow id=d4678e4134 href="http://dx.doi.org/10.1182/blood.V98.9.2865">Publisher Full Text </a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a name=d4678e4143 class=n-a></a>Piekarz RL, Frye R, Prince HM, <i> et al.</i>: Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. <i>Blood.</i> 2011; <b>117</b>(22): 5827–34. <a target=xrefwindow id=d4678e4154 href="http://www.ncbi.nlm.nih.gov/pubmed/21355097">PubMed Abstract </a> | <a target=xrefwindow id=d4678e4157 href="http://dx.doi.org/10.1182/blood-2010-10-312603">Publisher Full Text </a> | <a target=xrefwindow id=d4678e4161 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3112033">Free Full Text </a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/14264183"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4678e4170 class=n-a></a>Coiffier B, Pro B, Prince HM, <i> et al.</i>: Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. <i>J Clin Oncol.</i> 2012; <b>30</b>(6): 631–6. <a target=xrefwindow id=d4678e4181 href="http://www.ncbi.nlm.nih.gov/pubmed/22271479">PubMed Abstract </a> | <a target=xrefwindow id=d4678e4184 href="http://dx.doi.org/10.1200/JCO.2011.37.4223">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/14264183">F1000 Recommendation</a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a name=d4678e4198 class=n-a></a>Coiffier B, Pro B, Prince HM, <i> et al.</i>: Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. <i>J Hematol Oncol.</i> 2014; <b>7</b>: 11. <a target=xrefwindow id=d4678e4209 href="http://www.ncbi.nlm.nih.gov/pubmed/24456586">PubMed Abstract </a> | <a target=xrefwindow id=d4678e4212 href="http://dx.doi.org/10.1186/1756-8722-7-11">Publisher Full Text </a> | <a target=xrefwindow id=d4678e4216 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4016573">Free Full Text </a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/730593243"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4678e4225 class=n-a></a>Maruyama D, Tobinai K, Ogura M, <i> et al.</i>: Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study. <i>Int J Hematol.</i> 2017; <b>106</b>(5): 655–65. <a target=xrefwindow id=d4678e4236 href="http://www.ncbi.nlm.nih.gov/pubmed/28664499">PubMed Abstract </a> | <a target=xrefwindow id=d4678e4239 href="http://dx.doi.org/10.1007/s12185-017-2286-1">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/730593243">F1000 Recommendation</a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725789388"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4678e4252 class=n-a></a>Hui KF, Cheung AK, Choi CK, <i> et al.</i>: Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir. <i>Int J Cancer.</i> 2016; <b>138</b>(1): 125–36. <a target=xrefwindow id=d4678e4263 href="http://www.ncbi.nlm.nih.gov/pubmed/26205347">PubMed Abstract </a> | <a target=xrefwindow id=d4678e4266 href="http://dx.doi.org/10.1002/ijc.29698">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725789388">F1000 Recommendation</a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d4678e4279 class=n-a></a>Kim SJ, Kim JH, Ki CS, <i> et al.</i>: Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin. <i>Ann Oncol.</i> 2016; <b>27</b>(3): 508–13. <a target=xrefwindow id=d4678e4290 href="http://www.ncbi.nlm.nih.gov/pubmed/26658891">PubMed Abstract </a> | <a target=xrefwindow id=d4678e4293 href="http://dx.doi.org/10.1093/annonc/mdv596">Publisher Full Text </a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726283532"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4678e4302 class=n-a></a>Pellegrini C, Dodero A, Chiappella A, <i> et al.</i>: A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients. <i>J Hematol Oncol.</i> 2016; <b>9</b>: 38. <a target=xrefwindow id=d4678e4313 href="http://www.ncbi.nlm.nih.gov/pubmed/27071522">PubMed Abstract </a> | <a target=xrefwindow id=d4678e4316 href="http://dx.doi.org/10.1186/s13045-016-0266-1">Publisher Full Text </a> | <a target=xrefwindow id=d4678e4320 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4830040">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726283532">F1000 Recommendation</a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a name=d4678e4333 class=n-a></a>Reiman T, Savage KJ, Crump M, <i> et al.</i>: A Phase I Study of Romidepsin, Gemcitabine, Dexamethasone and Cisplatin Combination Therapy in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma: Canadian Cancer Trials Group Study LY. Annual Meeting of American Society of Hematology, <i>Blood.</i> 2016; <b>128</b>(22): 4162. <a target=xrefwindow id=d4678e4344 href="http://www.bloodjournal.org/content/128/22/4162">Reference Source</a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a name=d4678e4354 class=n-a></a>Chihara D, Oki Y, Westin JR, <i> et al.</i>: High Response Rate of Romidepsin in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: Updates of Phase I Trial. Annual Meeting of American Society of Hematology. <i>Blood.</i> 2015; <b>126</b>(23): 3987. <a target=xrefwindow id=d4678e4365 href="http://www.bloodjournal.org/content/126/23/3987?utm_source=TrendMD&amp;utm_medium=cpc&amp;utm_campaign=Blood_TrendMD_0">Reference Source</a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725240084"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4678e4374 class=n-a></a>Foss F, Advani R, Duvic M, <i> et al.</i>: A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. <i>Br J Haematol.</i> 2015; <b>168</b>(6): 811–9. <a target=xrefwindow id=d4678e4385 href="http://www.ncbi.nlm.nih.gov/pubmed/25404094">PubMed Abstract </a> | <a target=xrefwindow id=d4678e4388 href="http://dx.doi.org/10.1111/bjh.13222">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725240084">F1000 Recommendation</a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725582319"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4678e4401 class=n-a></a>O'Connor OA, Horwitz S, Masszi T, <i> et al.</i>: Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. <i>J Clin Oncol.</i> 2015; <b>33</b>(23): 2492–9. <a target=xrefwindow id=d4678e4412 href="http://www.ncbi.nlm.nih.gov/pubmed/26101246">PubMed Abstract </a> | <a target=xrefwindow id=d4678e4415 href="http://dx.doi.org/10.1200/JCO.2014.59.2782">Publisher Full Text </a> | <a target=xrefwindow id=d4678e4419 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5087312">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725582319">F1000 Recommendation</a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a name=d4678e4432 class=n-a></a>Horwitz S, OO C, Jurczak W, <i> et al.</i>: Belinostat in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL) subtype angioimmunoblastic T-cell lymphoma (AITL): Results from the pivotal BELIEF trial. 12th International Conference on Malignant Lymphoma, 2013. </span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a name=d4678e4444 class=n-a></a>Johnston PB, Cashen AF, Nikolinakos PG, <i> et al.</i>: Safe and Effective Treatment of Patients with Peripheral T-Cell Lymphoma (PTCL) with the Novel HDAC Inhibitor, Belinostat, in Combination with CHOP: Results of the Bel-CHOP Phase 1 Trial. Annual Meeting of American Society of Hematology. <i>Blood.</i> 2015; <b>126</b>(23): 253. <a target=xrefwindow id=d4678e4455 href="http://www.bloodjournal.org/content/126/23/253">Reference Source</a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a name=d4678e4464 class=n-a></a>Ning ZQ, Li ZB, Newman MJ, <i> et al.</i>: Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. <i>Cancer Chemother Pharmacol.</i> 2012; <b>69</b>(4): 901–9. <a target=xrefwindow id=d4678e4475 href="http://www.ncbi.nlm.nih.gov/pubmed/22080169">PubMed Abstract </a> | <a target=xrefwindow id=d4678e4478 href="http://dx.doi.org/10.1007/s00280-011-1766-x">Publisher Full Text </a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725585447"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4678e4488 class=n-a></a>Shi Y, Dong M, Hong X, <i> et al.</i>: Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. <i>Ann Oncol.</i> 2015; <b>26</b>(8): 1766–71. <a target=xrefwindow id=d4678e4499 href="http://www.ncbi.nlm.nih.gov/pubmed/26105599">PubMed Abstract </a> | <a target=xrefwindow id=d4678e4502 href="http://dx.doi.org/10.1093/annonc/mdv237">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725585447">F1000 Recommendation</a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731234011"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4678e4515 class=n-a></a>Shi Y, Jia B, Xu W, <i> et al.</i>: Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. <i>J Hematol Oncol.</i> 2017; <b>10</b>(1): 69. <a target=xrefwindow id=d4678e4526 href="http://www.ncbi.nlm.nih.gov/pubmed/28298231">PubMed Abstract </a> | <a target=xrefwindow id=d4678e4529 href="http://dx.doi.org/10.1186/s13045-017-0439-6">Publisher Full Text </a> | <a target=xrefwindow id=d4678e4533 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5351273">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731234011">F1000 Recommendation</a></span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation><a name=d4678e4546 class=n-a></a>Oki Y, Younes A, Copeland A, <i> et al.</i>: Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma. <i>Br J Haematol.</i> 2013; <b>162</b>(1): 138–41. <a target=xrefwindow id=d4678e4557 href="http://www.ncbi.nlm.nih.gov/pubmed/23590726">PubMed Abstract </a> | <a target=xrefwindow id=d4678e4560 href="http://dx.doi.org/10.1111/bjh.12326">Publisher Full Text </a></span></li><li><a name=ref-105 class=n-a></a><span class=label>105. </span>&nbsp;<span class=citation><a name=d4678e4569 class=n-a></a>Hopfinger G, Nösslinger T, Lang A, <i> et al.</i>: Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial. <i>Ann Hematol.</i> 2014; <b>93</b>(3): 459–62. <a target=xrefwindow id=d4678e4580 href="http://www.ncbi.nlm.nih.gov/pubmed/24441915">PubMed Abstract </a> | <a target=xrefwindow id=d4678e4583 href="http://dx.doi.org/10.1007/s00277-014-2009-0">Publisher Full Text </a></span></li><li><a name=ref-106 class=n-a></a><span class=label>106. </span>&nbsp;<span class=citation><a name=d4678e4592 class=n-a></a>Goh YT, Hwang WY, Diong CP, <i> et al.</i>: A Phase 2 Study of Panobinostat (PAN) in Combination with Bortezomib (BTZ) in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) or NK/T-Cell Lymphoma (NKL). Annual Meeting of American Society of Hematology, <i>Blood.</i> 2014; <b>124</b>(21): 503. <a target=xrefwindow id=d4678e4603 href="http://www.bloodjournal.org/content/124/21/503?sso-checked=true">Reference Source</a></span></li><li><a name=ref-107 class=n-a></a><span class=label>107. </span>&nbsp;<span class=citation><a name=d4678e4612 class=n-a></a>Kritharis A, Coyle M, Sharma J, <i> et al.</i>: Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities. <i>Blood.</i> 2015; <b>125</b>(16): 2471–6. <a target=xrefwindow id=d4678e4623 href="http://www.ncbi.nlm.nih.gov/pubmed/25736312">PubMed Abstract </a> | <a target=xrefwindow id=d4678e4626 href="http://dx.doi.org/10.1182/blood-2014-11-567792">Publisher Full Text </a> | <a target=xrefwindow id=d4678e4630 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4467884">Free Full Text </a></span></li><li><a name=ref-108 class=n-a></a><span class=label>108. </span>&nbsp;<span class=citation><a name=d4678e4640 class=n-a></a>Morschhauser F, Fitoussi O, Haioun C, <i> et al.</i>: A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. <i>Eur J Cancer.</i> 2013; <b>49</b>(13): 2869–76. <a target=xrefwindow id=d4678e4651 href="http://www.ncbi.nlm.nih.gov/pubmed/23731832">PubMed Abstract </a> | <a target=xrefwindow id=d4678e4654 href="http://dx.doi.org/10.1016/j.ejca.2013.04.029">Publisher Full Text </a></span></li><li><a name=ref-109 class=n-a></a><span class=label>109. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725089388"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4678e4663 class=n-a></a>Toumishey E, Prasad A, Dueck G, <i> et al.</i>: Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma. <i>Cancer.</i> 2015; <b>121</b>(5): 716–23. <a target=xrefwindow id=d4678e4674 href="http://www.ncbi.nlm.nih.gov/pubmed/25355245">PubMed Abstract </a> | <a target=xrefwindow id=d4678e4677 href="http://dx.doi.org/10.1002/cncr.29103">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725089388">F1000 Recommendation</a></span></li><li><a name=ref-110 class=n-a></a><span class=label>110. </span>&nbsp;<span class=citation><a name=d4678e4690 class=n-a></a>Mehta-Shah N, Moskowitz AJ, Lunning M, <i> et al.</i>: A Phase Ib/IIa Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory T-Cell Lymphomas. Annual Meeting of American Society of Hematology, <i>Blood.</i> 2016; <b>128</b>(22): 2991. <a target=xrefwindow id=d4678e4701 href="http://www.bloodjournal.org/content/128/22/2991">Reference Source</a></span></li><li><a name=ref-111 class=n-a></a><span class=label>111. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727697987"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4678e4710 class=n-a></a>Li L, Duan W, Zhang L, <i> et al.</i>: The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers. <i>Br J Haematol.</i> 2017; <b>178</b>(5): 772–80. <a target=xrefwindow id=d4678e4721 href="http://www.ncbi.nlm.nih.gov/pubmed/28597542">PubMed Abstract </a> | <a target=xrefwindow id=d4678e4724 href="http://dx.doi.org/10.1111/bjh.14763">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727697987">F1000 Recommendation</a></span></li><li><a name=ref-112 class=n-a></a><span class=label>112. </span>&nbsp;<span class=citation><a name=d4678e4737 class=n-a></a>Zinzani PL, Musuraca G, Tani M, <i> et al.</i>: Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. <i>J Clin Oncol.</i> 2007; <b>25</b>(27): 4293–7. <a target=xrefwindow id=d4678e4748 href="http://www.ncbi.nlm.nih.gov/pubmed/17709797">PubMed Abstract </a> | <a target=xrefwindow id=d4678e4751 href="http://dx.doi.org/10.1200/JCO.2007.11.4207">Publisher Full Text </a></span></li><li><a name=ref-113 class=n-a></a><span class=label>113. </span>&nbsp;<span class=citation><a name=d4678e4760 class=n-a></a>Arlt A, Vorndamm J, Breitenbroich M, <i> et al.</i>: Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. <i>Oncogene.</i> 2001; <b>20</b>(7): 859–68. <a target=xrefwindow id=d4678e4771 href="http://www.ncbi.nlm.nih.gov/pubmed/11314019">PubMed Abstract </a> | <a target=xrefwindow id=d4678e4774 href="http://dx.doi.org/10.1038/sj.onc.1204168">Publisher Full Text </a></span></li><li><a name=ref-114 class=n-a></a><span class=label>114. </span>&nbsp;<span class=citation><a name=d4678e4784 class=n-a></a>Kim SJ, Yoon DH, Kang HJ, <i> et al.</i>: Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial. <i>Eur J Cancer.</i> 2012; <b>48</b>(17): 3223–31. <a target=xrefwindow id=d4678e4795 href="http://www.ncbi.nlm.nih.gov/pubmed/22770877">PubMed Abstract </a> | <a target=xrefwindow id=d4678e4798 href="http://dx.doi.org/10.1016/j.ejca.2012.06.003">Publisher Full Text </a></span></li><li><a name=ref-115 class=n-a></a><span class=label>115. </span>&nbsp;<span class=citation><a name=d4678e4807 class=n-a></a>Delmer A, Fitoussi O, Gaulard P, <i> et al.</i>: A phase II study of bortezomib in combination with intensified CHOP-like regimen (ACVBP) in patients with previously untreated T-cell lymphoma: results of the GELA LNH05-1T trial. Annual Meeting of American Society of Clinical Oncology, <i>J Clin Oncol.</i> 2009; <b>27</b>(15S): 8554. <a target=xrefwindow id=d4678e4818 href="http://ascopubs.org/doi/abs/10.1200/jco.2009.27.15s.8554">Reference Source</a></span></li><li><a name=ref-116 class=n-a></a><span class=label>116. </span>&nbsp;<span class=citation><a name=d4678e4827 class=n-a></a>Liu P, Cheng H, Roberts TM, <i> et al.</i>: Targeting the phosphoinositide 3-kinase pathway in cancer. <i>Nat Rev Drug Discov.</i> 2009; <b>8</b>(8): 627–44. <a target=xrefwindow id=d4678e4838 href="http://www.ncbi.nlm.nih.gov/pubmed/19644473">PubMed Abstract </a> | <a target=xrefwindow id=d4678e4841 href="http://dx.doi.org/10.1038/nrd2926">Publisher Full Text </a> | <a target=xrefwindow id=d4678e4845 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3142564">Free Full Text </a></span></li><li><a name=ref-117 class=n-a></a><span class=label>117. </span>&nbsp;<span class=citation><a name=d4678e4854 class=n-a></a>Steven M, Horwitz PP, Flinn I, <i> et al.</i>: Duvelisib (IPI-145), a Phosphoinositide-3-Kinase-δ,γ Inhibitor, Shows Activity in Patients with Relapsed/Refractory T-Cell Lymphoma. Annual Meeting of American Society of Hematology. <i>Blood.</i> 2014; <b>124</b>(21): 803. <a target=xrefwindow id=d4678e4865 href="http://www.bloodjournal.org/content/124/21/803">Reference Source</a></span></li><li><a name=ref-118 class=n-a></a><span class=label>118. </span>&nbsp;<span class=citation><a name=d4678e4874 class=n-a></a>Oki Y, Zain J, Haverkos B, <i> et al.</i>: Dual Pi3k δ/γ Inhibitor Rp6530 In Patients With Relapsed/Refractory T-Cell Lymphoma: Dose Escalation Findings. <i>Hematol Oncol.</i> 2017; <b>35</b>(Supplement S2): 412. <a target=xrefwindow id=d4678e4885 href="http://dx.doi.org/10.1002/hon.2439_191">Publisher Full Text </a></span></li><li><a name=ref-119 class=n-a></a><span class=label>119. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727738600"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4678e4894 class=n-a></a>Dreyling M, Morschhauser F, Bouabdallah K, <i> et al.</i>: Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. <i>Ann Oncol.</i> 2017; <b>28</b>(9): 2169–78. <a target=xrefwindow id=d4678e4905 href="http://www.ncbi.nlm.nih.gov/pubmed/28633365">PubMed Abstract </a> | <a target=xrefwindow id=d4678e4908 href="http://dx.doi.org/10.1093/annonc/mdx289">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727738600">F1000 Recommendation</a></span></li><li><a name=ref-120 class=n-a></a><span class=label>120. </span>&nbsp;<span class=citation><a name=d4678e4922 class=n-a></a>Hong JY, Hong ME, Choi MK, <i> et al.</i>: The clinical significance of activated p-AKT expression in peripheral T-cell lymphoma. <i>Anticancer Res.</i> 2015; <b>35</b>(4): 2465–74. <a target=xrefwindow id=d4678e4933 href="http://www.ncbi.nlm.nih.gov/pubmed/25862915">PubMed Abstract </a></span></li><li><a name=ref-121 class=n-a></a><span class=label>121. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725675529"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4678e4942 class=n-a></a>Oki Y, Fanale M, Romaguera J, <i> et al.</i>: Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. <i>Br J Haematol.</i> 2015; <b>171</b>(4): 463–70. <a target=xrefwindow id=d4678e4953 href="http://www.ncbi.nlm.nih.gov/pubmed/26213141">PubMed Abstract </a> | <a target=xrefwindow id=d4678e4956 href="http://dx.doi.org/10.1111/bjh.13603">Publisher Full Text </a> | <a target=xrefwindow id=d4678e4960 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5278973">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725675529">F1000 Recommendation</a></span></li><li><a name=ref-122 class=n-a></a><span class=label>122. </span>&nbsp;<span class=citation><a name=d4678e4973 class=n-a></a>Pourdehnad M, Truitt ML, Siddiqi IN, <i> et al.</i>: Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers. <i>Proc Natl Acad Sci U S A.</i> 2013; <b>110</b>(29): 11988–93. <a target=xrefwindow id=d4678e4984 href="http://www.ncbi.nlm.nih.gov/pubmed/23803853">PubMed Abstract </a> | <a target=xrefwindow id=d4678e4987 href="http://dx.doi.org/10.1073/pnas.1310230110">Publisher Full Text </a> | <a target=xrefwindow id=d4678e4991 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3718086">Free Full Text </a></span></li><li><a name=ref-123 class=n-a></a><span class=label>123. </span>&nbsp;<span class=citation><a name=d4678e5000 class=n-a></a>Kim SJ, Shin DY, Kim JS, <i> et al.</i>: A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas. <i>Ann Oncol.</i> 2016; <b>27</b>(4): 712–8. <a target=xrefwindow id=d4678e5011 href="http://www.ncbi.nlm.nih.gov/pubmed/26861608">PubMed Abstract </a> | <a target=xrefwindow id=d4678e5014 href="http://dx.doi.org/10.1093/annonc/mdv624">Publisher Full Text </a></span></li><li><a name=ref-124 class=n-a></a><span class=label>124. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725453797"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4678e5023 class=n-a></a>Witzig TE, Reeder C, Han JJ, <i> et al.</i>: The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. <i>Blood.</i> 2015; <b>126</b>(3): 328–35. <a target=xrefwindow id=d4678e5034 href="http://www.ncbi.nlm.nih.gov/pubmed/25921059">PubMed Abstract </a> | <a target=xrefwindow id=d4678e5037 href="http://dx.doi.org/10.1182/blood-2015-02-629543">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725453797">F1000 Recommendation</a></span></li><li><a name=ref-125 class=n-a></a><span class=label>125. </span>&nbsp;<span class=citation><a name=d4678e5050 class=n-a></a>Damaj G, Gressin R, Bouabdallah K, <i> et al.</i>: Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. <i>J Clin Oncol.</i> 2013; <b>31</b>(1): 104–10. <a target=xrefwindow id=d4678e5061 href="http://www.ncbi.nlm.nih.gov/pubmed/23109692">PubMed Abstract </a> | <a target=xrefwindow id=d4678e5064 href="http://dx.doi.org/10.1200/JCO.2012.43.7285">Publisher Full Text </a></span></li><li><a name=ref-126 class=n-a></a><span class=label>126. </span>&nbsp;<span class=citation><a name=d4678e5074 class=n-a></a>Park B, Kim W, Suh C, <i> et al.</i>: A Phase II Trial Of Bendamustine, Carboplatin And Dexamethasone (BCD) For Refractory Or Relapsed Peripheral T-Cell Lymphoma (BENCART): A Consortium For Improving Survival Of Lymphoma (CISL) Trial. <i>Hematol Oncol.</i> 2017; <b>35</b>(S2): 393–4. <a target=xrefwindow id=d4678e5085 href="http://dx.doi.org/10.1002/hon.2439_161">Publisher Full Text </a></span></li><li><a name=ref-127 class=n-a></a><span class=label>127. </span>&nbsp;<span class=citation><a name=d4678e5094 class=n-a></a>Kanagal-Shamanna R, Lehman NL, O'Donnell JP, <i> et al.</i>: Differential expression of aurora-A kinase in T-cell lymphomas. <i>Mod Pathol.</i> 2013; <b>26</b>(5): 640–7. <a target=xrefwindow id=d4678e5105 href="http://www.ncbi.nlm.nih.gov/pubmed/23411487">PubMed Abstract </a> | <a target=xrefwindow id=d4678e5108 href="http://dx.doi.org/10.1038/modpathol.2012.211">Publisher Full Text </a> | <a target=xrefwindow id=d4678e5112 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5007132">Free Full Text </a></span></li><li><a name=ref-128 class=n-a></a><span class=label>128. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718112987"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4678e5121 class=n-a></a>Friedberg JW, Mahadevan D, Cebula E, <i> et al.</i>: Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. <i>J Clin Oncol.</i> 2014; <b>32</b>(1): 44–50. <a target=xrefwindow id=d4678e5132 href="http://www.ncbi.nlm.nih.gov/pubmed/24043741">PubMed Abstract </a> | <a target=xrefwindow id=d4678e5135 href="http://dx.doi.org/10.1200/JCO.2012.46.8793">Publisher Full Text </a> | <a target=xrefwindow id=d4678e5139 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3867644">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718112987">F1000 Recommendation</a></span></li><li><a name=ref-129 class=n-a></a><span class=label>129. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725563730"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4678e5152 class=n-a></a>Barr PM, Li H, Spier C, <i> et al.</i>: Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. <i>J Clin Oncol.</i> 2015; <b>33</b>(21): 2399–404. <a target=xrefwindow id=d4678e5163 href="http://www.ncbi.nlm.nih.gov/pubmed/26077240">PubMed Abstract </a> | <a target=xrefwindow id=d4678e5166 href="http://dx.doi.org/10.1200/JCO.2014.60.6327">Publisher Full Text </a> | <a target=xrefwindow id=d4678e5170 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4500834">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725563730">F1000 Recommendation</a></span></li><li><a name=ref-130 class=n-a></a><span class=label>130. </span>&nbsp;<span class=citation><a name=d4678e5183 class=n-a></a>O'Connor OA, Özcan M, Jacobsen ED, <i> et al.</i>: First Multicenter, Randomized Phase 3 Study in Patients (Pts) with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice. Annual Meeting of American Society of Hematology. <i>Blood.</i> 2015; <b>126</b>(23): 341. <a target=xrefwindow id=d4678e5194 href="http://www.bloodjournal.org/content/126/23/341">Reference Source</a></span></li><li><a name=ref-131 class=n-a></a><span class=label>131. </span>&nbsp;<span class=citation><a name=d4678e5203 class=n-a></a>Witzig TE, Tang H, Micallef IN, <i> et al.</i>: Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. <i>Blood.</i> 2011; <b>118</b>(18): 4882–9. <a target=xrefwindow id=d4678e5214 href="http://www.ncbi.nlm.nih.gov/pubmed/21725056">PubMed Abstract </a> | <a target=xrefwindow id=d4678e5217 href="http://dx.doi.org/10.1182/blood-2011-02-334904">Publisher Full Text </a> | <a target=xrefwindow id=d4678e5221 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3208296">Free Full Text </a></span></li><li><a name=ref-132 class=n-a></a><span class=label>132. </span>&nbsp;<span class=citation><a name=d4678e5231 class=n-a></a>Witzig T, Sokol L, Jacobsen E, <i> et al.</i>: Preliminary Results From An Open-Label, Phase II Study Of Tipifarnib In Relapsed Or Refractory Peripheral T-Cell Lymphoma. <i>Hematol Oncol.</i> 2017; <b>35</b>(S2): 251–2. <a target=xrefwindow id=d4678e5242 href="http://dx.doi.org/10.1002/hon.2438_115">Publisher Full Text </a></span></li><li><a name=ref-133 class=n-a></a><span class=label>133. </span>&nbsp;<span class=citation><a name=d4678e5251 class=n-a></a>Stuart SD, Schauble A, Gupta S, <i> et al.</i>: A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process. <i>Cancer Metab.</i> 2014; <b>2</b>(1): 4. <a target=xrefwindow id=d4678e5262 href="http://www.ncbi.nlm.nih.gov/pubmed/24612826">PubMed Abstract </a> | <a target=xrefwindow id=d4678e5265 href="http://dx.doi.org/10.1186/2049-3002-2-4">Publisher Full Text </a> | <a target=xrefwindow id=d4678e5269 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4108059">Free Full Text </a></span></li><li><a name=ref-134 class=n-a></a><span class=label>134. </span>&nbsp;<span class=citation><a name=d4678e5278 class=n-a></a>Pardee TS, Lee K, Luddy J, <i> et al.</i>: A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies. <i>Clin Cancer Res.</i> 2014; <b>20</b>(20): 5255–64. <a target=xrefwindow id=d4678e5289 href="http://www.ncbi.nlm.nih.gov/pubmed/25165100">PubMed Abstract </a> | <a target=xrefwindow id=d4678e5292 href="http://dx.doi.org/10.1158/1078-0432.CCR-14-1019">Publisher Full Text </a> | <a target=xrefwindow id=d4678e5296 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4199870">Free Full Text </a></span></li><li><a name=ref-135 class=n-a></a><span class=label>135. </span>&nbsp;<span class=citation><a name=d4678e5305 class=n-a></a>Lamar ZS, Isom S, Vaidya R, <i> et al.</i>: Phase I Dose-Escalation Study of Cpi-613, in Combination with Bendamustine, in Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma. Annual Meeting of American Society of Hematology. <i>Blood.</i> 2016; <b>128</b>(22): 4163. <a target=xrefwindow id=d4678e5316 href="http://www.bloodjournal.org/content/128/22/4163">Reference Source</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 12 Dec 2017</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/6-2123.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/6-2123.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Division of Hematology-Oncology, Department of Medicine, Chung-Ang University , Seoul, South Korea<br/> <sup>2</sup> Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul, South Korea<br/> <p> <div class=margin-bottom> Jun Ho Yi <br/> <span>Roles: </span> Supervision, Writing – Original Draft Preparation </div> <div class=margin-bottom> Seok Jin Kim <br/> <span>Roles: </span> Project Administration, Supervision </div> <div class=margin-bottom> Won Seog Kim <br/> <span>Roles: </span> Supervision, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/6-2123/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 12 Dec 2017, 6:2123 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.12573.1">https://doi.org/10.12688/f1000research.12573.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2017 Yi JH <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=13616 data-id=12573 data-downloads="" data-views="" data-scholar="10.12688/f1000research.12573.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/6-2123/v1/pdf?article_uuid=191d0b13-885c-44e1-a3a2-6196ff0434fa" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.12573.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Yi JH, Kim SJ and Kim WS. Recent advances in understanding and managing T-cell lymphoma [version 1; peer review: 2 approved] <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):2123 (<a href="https://doi.org/10.12688/f1000research.12573.1" target=_blank>https://doi.org/10.12688/f1000research.12573.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=12573 id=mobile-track-article-signin-12573 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/12573?target=/articles/6-2123.html"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=13616 /> <input name=articleId type=hidden value=12573 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Christian Gisselbrecht</strong>, Institut d'Hématologie, Hôpital Saint-Louis, France </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Shigeru Chiba</strong>, Department of Hematology, Faculty of Medicine, University of Tsukuba, Japan </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 12 Dec 2017</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/6-2123.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/6-2123.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=28648-28593></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=28646-28596></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/6-2123/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>12 Dec 17</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Christian Gisselbrecht</strong>, Institut d'Hématologie, Hôpital Saint-Louis, France </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Shigeru Chiba</strong>, Department of Hematology, Faculty of Medicine, University of Tsukuba, Japan </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/6-2123.html&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/6-2123/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent advances in understanding and managing...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/6-2123/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/6-2123/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/6-2123/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Yi JH et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/6-2123/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/6-2123",
            templates : {
                twitter : "Recent advances in understanding and managing T-cell lymphoma. Yi JH et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/6-2123/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent advances in understanding and managing T-cell lymphoma", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent advances in understanding and managing T-cell lymphoma", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/12573/13616")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "13616");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "28593": 0,
                           "28596": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "841e4cfc-16fb-4c36-bd63-2046f99a908f";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-2123.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-2123.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-2123.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/6-2123.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/6-2123.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>